Identification and Characterization of Rare Variants in Cholinergic Nicotinic Receptor Genes and their Contribution to Substance Dependence by Haller, Gabriel Emanuel
Washington University in St. Louis
Washington University Open Scholarship
All Theses and Dissertations (ETDs)
Summer 6-6-2013
Identification and Characterization of Rare Variants
in Cholinergic Nicotinic Receptor Genes and their
Contribution to Substance Dependence
Gabriel Emanuel Haller
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/etd
This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All
Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.
Recommended Citation
Haller, Gabriel Emanuel, "Identification and Characterization of Rare Variants in Cholinergic Nicotinic Receptor Genes and their
Contribution to Substance Dependence" (2013). All Theses and Dissertations (ETDs). 1133.
https://openscholarship.wustl.edu/etd/1133
 
 
 
 
 
WASHINGTON UNIVERSITY IN ST. LOUIS 
 
Division of Biology and Biomedical Sciences 
Human and Statistical Genetics 
 
 
Dissertation Examination Committee: 
Alison Goate, Chair 
Michael Bruchas 
Robi Mitra 
John Rice 
Nancy Saccone 
Joe Henry Steinbach 
 
 
 
 
 
Identification and Characterization of Rare Variants in Cholinergic Nicotinic Receptor 
Genes and their Contribution to Substance Dependence  
 
by Gabriel Emanuel Haller 
 
 
 
 
A dissertation presented to the  
Graduate School of Arts and Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
 
 
 
August 2013 
 
St. Louis, Missouri  
  
	   ii	  
 
Table of Contents   
 
Acknowledgements     ...................................................................................................     iv 
Abstract of the Dissertation     ......................................................................................     vi 
 
Chapter 1. Introduction and Perspective     ..............................................................      1 
 
Chapter 2. Identification of rare variants in cholinergic nicotinic receptor genes and 
their association with nicotine dependence  
 
Summary     ...................................................................................................................  31  
Introduction     ...............................................................................................................  32  
Methods     .....................................................................................................................  34  
Results     .......................................................................................................................  38  
Discussion     .................................................................................................................  43  
Figures     .......................................................................................................................  46  
 
Chapter 3. Identification of rare variants in cholinergic nicotinic receptor genes and 
their association with alcohol and cocaine  
 
Summary     ...................................................................................................................  53  
Introduction     ...............................................................................................................  54  
Methods     .....................................................................................................................  56  
Results     .......................................................................................................................  59  
Discussion     .................................................................................................................  65  
Figures     .......................................................................................................................  69  
	   iii	  
 
Chapter 4. Functional characterization of rare variants in CHRNB4 to improve the 
association between CHRNB4 and nicotine dependence 
 
Summary     ...................................................................................................................  81  
Introduction     ...............................................................................................................  82  
Methods     .....................................................................................................................  85  
Results     .......................................................................................................................  93  
Discussion     .................................................................................................................  97  
Figures     .......................................................................................................................  101  
 
Chapter 5.  Conclusions and Future Directions     ...................................................  159 
 
References     ................................................................................................................  170 
 
 
	   iv	  
Acknowledgements  
First and foremost, I want to thank Dr. Alison Goate, who from the beginning of 
my time in the lab has treated me more as a peer than an employee. I am so glad I was 
able to train with her, both because of her wealth of knowledge and countless great ideas, 
but also for her kindness as a mentor.  
I would also like to thank the other members of the Goate lab, past and present, 
who have made work like home. In particular, my climbing partner, John Budde, without 
whom no Sequenom would have been done and no crazy idea would have been given 
hope.  I would like to thank the members of my thesis committee, Dr. Rob Mitra, Dr. Joe 
Henry Steinbach, Dr. John Rice, Dr. Anne Bowcock, Dr. Nancy Saccone and Dr. Michael 
Bruchas for all of their help over the years and for taking the time to help me grow as a 
scientist. Much of this work would have been very hard without the help early on of Todd 
Druley and Francesco Vallania, then both members of the Mitra lab. I am very grateful 
for their help both devising and performing the pooled sequencing that is at the center of 
this work. Absolutely none of the functional data presented as part of this dissertation 
would be possible without the great work of Joe Henry Steinbach, Gustav Akk and Ping 
Li. I cannot thank them enough.   
I would like to of course thank the lead investigators directing data collection: 
Laura Bierut, Naomi Breslau, Dorothy Hatsukami, and Eric Johnson. In particular, I 
would like to thank Laura Bierut for all of her help as leader of the COGEND project.  
The COGEND project is a collaborative research group and part of the National Institute 
on Drug Abuse (NIDA) Genetics Consortium.  Subject collection was supported by NIH 
grant P01 CA89392 (PI - L Bierut) from the National Cancer Institute (NCI). Phenotypic 
	   v	  
and genotypic data are stored in the NIDA Center for Genetic Studies (NCGS) at 
http://zork.wustl.edu/ under NIDA Contract HHSN271200477451C (PIs J Tischfield and 
J Rice). Electrophysiological studies supported by NIH grant R21 DA26918 (G. Akk) 
and NINSD grant R01 NS22356 (J.H. Steinbach). 
The COGA project is a collaborative research group and part of the National 
Institute on Drug Abuse (NIDA) Genetics Consortium.  Subject collection was supported 
by NIH grant XX (PI - L Bierut) from the NIXX. Phenotypic and genotypic data are 
stored in the NIDA Center for Genetic Studies (NCGS) at http://zork.wustl.edu/ under 
NIDA Contract HHSN271200477451C (PIs J Tischfield and J Rice).  
I would very much like to thank my family. My parents and my sisters, as well as 
my entire extended family, have always supported my desire to be a scientist and a 
geneticist. They have never tried to tell me what to be, just that I should do what I love.  
Lastly, I thank my fiancée Brooke Sadler. Thank you for everything! 
 
	   vi	  
ABSTRACT OF THE DISSERTATION 
 
Identification and Characterization of Rare Variants in Cholinergic Nicotinic Receptor 
Genes and their Contribution to Substance Dependence.  
 
by 
 
Gabriel Emanuel Haller 
 
Doctor of Philosophy in Biology and Biomedical Sciences  
Human and Statistical Genetics Program 
 
Washington University in St. Louis, 2013 
 
Professor Alison Goate, Chairperson 
 
 
Genome-wide association studies (GWAS) have identified common variation in 
the CHRNA5-CHRNA3-CHRNB4 and CHRNA6-CHRNB3 gene clusters that contribute to 
nicotine dependence. However, the role of rare variation in risk for substance dependence 
in these nicotinic receptor genes has not been studied.  
In order to investigate the role rare variants play in the development of nicotine 
dependence, we undertook pooled sequencing of the coding regions and flanking 
sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and CHRNB3 genes in 710 
African Americans (461 nicotine dependent (ND) cases and 249 smokers with no 
symptoms of dependence (controls)) and 2055 European Americans (1062 ND cases and 
993 controls) from the Collaborative Study of the Genetics of Nicotine Dependence 
(COGEND). Carrier status of individuals harboring rare non-synonymous variants at 
conserved sites in each of these genes was then compared in cases and controls to test for 
an association with nicotine dependence. We find a reduced risk for nicotine dependence 
among carriers of missense variants at conserved residues in CHRNB4 in African 
Americans and European Americans.  
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We next aimed to determine whether rare genetic variation in these genes 
influence risk for developing alcohol or cocaine dependence, two conditions highly 
comorbid with nicotine dependence. We undertook pooled sequencing of the coding 
regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and 
CHRNB3 genes in 287 African Americans (147 DSM-IV alcohol dependent cases and 
140 controls) and 1028 European Americans (480 DSM-IV alcohol dependent cases and 
548 controls) individuals from the Collaborative Study of the Genetics of Alcoholism 
(COGA). For European Americans, we find increased DSM-IV cocaine dependence 
symptoms (famSKAT p= 2x10-4) and increased DSM-IV alcohol dependence symptoms 
(famSKAT p= 5x10-4) among carriers of missense variants in CHRNB3. For African 
Americans, we find decreased cocaine dependence symptoms among carriers of missense 
variants in CHRNA3 (famSKAT p= 0.006). 
Finally, we sought to determine the functional impact of rare variants in CHRNB4 
harbored by individuals in these two cohorts. A total of 10 variants in CHRNB4 observed 
in the COGEND cohort were investigated. One variant in CHRNA3 was also functionally 
tested as it is high linkage disequilibrium with another rare missense variant in CHRNB4. 
We find several variants that alter cellular response either to nicotine or acetylcholine as 
well as many variants that alter cell-surface protein expression as measured by cell-
surface ELISA without altering either CHRNB4 mRNA or total β4 protein as measured 
by western blot. Further, when we integrate these in vitro findings into a model of 
association with nicotine dependence related traits, we improve the association, 
suggesting that the success of future association analyses in these and potentially many 
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other genes across the genome, may depend greatly on functional assessment of observed 
genetic variation.  
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Chapter 1. Introduction and Perspective1 
Complex Trait Genetics 
 A complex genetic trait is defined as a heritable trait for which the genetic 
contributors are not limited to one or a small number of genes. This is in stark contrast to 
what geneticists refer to as “Mendelian” traits or diseases for which the genetic causes are 
comparatively simple, being limited to one or a handful of genes or loci. Much effort in 
the preceding decades has been spent trying to understand the genetic underpinnings of 
complex traits. Before the advent of inexpensive single nucleotide polymorphism (SNP) 
genotyping microarrays, limited numbers of variable sites across the genome were 
interrogated either to ask very specific questions about genes with high prior probabilities 
of contributing to a trait or to perform linkage scans in families to identify large genomic 
regions segregating with disease/trait status. In each case, genes underlying complex 
traits were identified, but with limited success. More recently, microarrays able to 
genotype hundreds of thousands or millions of SNPs across the genome have been used 
to identify thousands of common genetic variants contributing to complex disease risk. 
So-called genome-wide association studies (GWAS) were then performed using these 
genotyping arrays in large cohorts of cases, individuals with a given disease or trait, and 
controls, individuals specifically ascertained to be free of disease or not have a given 
trait1. The variants significantly associated with the tested diseases or traits have 
generally had small effects, however, with individuals heterozygous at these sites having 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  Portions	  of	  this	  chapter	  are	  adapted	  from:	  Haller,	  G.,	  Druley,	  T.,	  Vallania,	  F.L.,	  Mitra,	  R.D.,	  Li,	  P.,	  Akk,	  G.,	  Steinbach,	  J.H.,	  Breslau,	  N.,	  Johnson,	  E.,	  Hatsukami,	  D.	  et	  al.	  (2012)	  Rare	  missense	  variants	  in	  CHRNB4	  are	  associated	  with	  reduced	  risk	  of	  nicotine	  dependence.	  Human	  molecular	  genetics,	  21,	  647-­‐655.	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odds of developing disease of 1.1-1.5 compared to non-carriers. These small effect-sizes 
have demanded that investigators increase sample size considerably in order to have the 
statistical power necessary to find significant associations. One of the largest studies of a 
complex trait, consisting of ~250,000 subjects, was for anthropomorphic traits such as 
height and body-mass index (BMI; height/weight2) 2. This study was able to find 69 
genome-wide significant SNPs associated with one of their traits of interest but were still 
only able to explain ~5% of BMI with the genome-wide significantly associated SNPs 
(Figure 1.1).  
 More recent studies of complex traits have utilized the newly developed method of 
exome sequencing, i.e. only sequencing the protein-coding portion of the genome (~1.5% 
of the genome)3-5 or have used genotyping microarrays designed to only interrogate the 
protein-altering genetic variants (exome chip) . Exome sequencing involves using 
genomic capture techniques, i.e. hybridizing sheared genomic DNA with biotinylated 
RNA baits complementary to the protein-coding regions of the genome and then washing 
away any DNA fragments that did not hybridize (Figure 1.2). For the exome-chip, only 
protein-altering variants are genotyped that were found in multiple individuals from 
~12,000 sequenced exomes and genomes culled from the 1000 genomes project 6, the 
NHLBI Exome Sequencing Project7 and others. In each case, the population frequency of 
variants is generally much lower than the frequency of variants investigated as part of 
genome-wide association studies, as protein-altering variants are more likely to be 
negatively selected in populations due to their increased probability of deleterious effects 
and as a result are also more likely to be at low frequencies in populations 8. This reduced 
population frequency, however, also reduces power to detect associations between 
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complex traits and these variants 9. As such, very few of the studies utilizing these 
methods have had much success identifying novel genes or loci underlying complex 
disease. Even using collapsing methods wherein rare variants are combined to create 
pseudo-common variants or using complex statistical frameworks, very few examples 
exist of large exome-sequencing efforts that have yielded significant findings and many 
of these have been for de novo variants in schizophrenia, autism and cancer 10-14. As 
exome sequencing is still rather expensive, however, many of the exome sequencing 
studies have been made of many small samples pieced together from disparate sources 
and as such have lacked power.  Regarding studies utilizing the exome-chip, the lack of 
positive results may be in part due to the fact that rarer variants are harder to call using 
currently available genotype clustering algorithms. The result of this is an increased 
probability of incorrect genotyping calling which in turn increases both the false positive 
and false negative rates in association testing done with the resultant genotypes.  Very 
few studies, therefore, have yet been published using exome-chip data 15. 
 Overall, complex genetic diseases have garnered substantial attention in the recent 
past, but only small amounts of variability in the traits and diseases under study have 
been explained using current techniques 16. This can be explained in part by a lack of 
attention paid to rarer variants and in part due to a lack of power in all studies. It is likely 
that complex traits and diseases are the product of hundreds if not thousands of variants 
of all frequencies, many with near infinitesimal effect sizes. It will likely be important in 
the future to develop ways of integrating knowledge of specific variant’s impact on 
protein function or gene expression, etc. into models of association.  
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Genetics of Nicotine Dependence 
Substance abuse is one the leading causes of preventable death in the United States and 
across the world. Cigarette smoking, for instance, dramatically increases risk of 
developing lung cancer, chronic obstructive pulmonary disease (COPD), coronary heart 
disease and stroke and is overall the number one cause of preventable death worldwide 
2,17. Figure 1.3 shows survival curves for individuals who either never smoked, used to 
smoke or smoke differing numbers of cigarettes per day on average 18. Additionally, 
alcohol dependence represents a considerable health and economic burden due to 
substance use related morbidity, accidents and imprisonment 19. As such, it is critical to 
understand the underlying causes of substance-related behavior and substance 
dependence (SD). Studies have suggested that genes, the environment and the interplay 
between the two play an important role in determining whether or not a person will 
become substance dependent 20,21. For instance, an individual who has never been 
exposed to nicotine cannot be nicotine dependent. If one is concerned with elucidating 
genes underlying the effect of nicotine on smoking behavior, it is important to correct for 
environmental factors whenever possible. It is clear from epidemiological studies and in 
ascertaining individuals for genetic studies that there exist different strata of smokers. 
There are those who have smoked cigarettes, but not enough to elicit sustained activation 
of reward pathways in the brain (~22% of smokers), those who smoke regularly but show 
few signs of being nicotine dependent (~33% of smokers) and finally those who show 
high levels of nicotine addiction (~44% of smokers). Figure 1.4 shows the proportions of 
individuals from a population-based sampling of individuals who made the various 
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transitions to nicotine dependence and the heritability estimates for both smoking 
initiation and nicotine dependence 22. Additionally, because there is strong comorbidity 
among types of substance dependence and it is thought that though there are substance 
specific genetic and environmental risk factors, some evidence suggests that much of the 
genetic vulnerability to different substances is shared 23,24.  
Using the Fagerström Test for Nicotine Dependence (FTND), a quantitative 
measure of nicotine dependence can be calculated 25,26. The FTND questionnaire consists 
of six questions (4 one point questions and 2 three point questions) giving a maximum 
score of 10 for individuals with strong nicotine dependence (Figure 1.5). A major 
component of the FTND is the number of cigarettes smoked per day (CPD), one of the 
two three point questions, making CPD another quantitative measure of nicotine 
dependence similar to and highly correlated with FTND score. Additionally, we can, I we 
do for our studies, exclude all individuals who have never smoked at least 100 cigarettes 
in their life. This corrects for the GxE interaction between nicotine exposure and 
associated gene variants with respect to nicotine dependence. It is for these reasons that 
we will choose individuals to sequence from the extremes of FTND score and CPD.  
 Studies of families and twins have suggested a strong genetic contribution to the 
development of multiple nicotine related traits. One such study found that ~50% of the 
variance in smoking persistence could be accounted for by genetic factors 27. 
Additionally, age of initiation was also found to be highly heritable 28. A meta-analysis of 
several twin studies also identified a role for genetics in the initiation of smoking 29. A 
number of heritability studies have investigated generalized drug addiction, often 
including nicotine dependence as one of the drugs on which an individual could be 
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dependent. One such study found that there was as much as an 8-fold increase in risk for 
relatives of drug-dependent individuals compared to individuals without drug-dependent 
relatives 30. Twin studies have also given credence to the genetic contributions to 
smoking behavior. Many groups have found that the concordance for smoking was 
significantly higher in monozygotic male twin pairs than in dizygotic male twins 27,31-34.  
 Genetic variation in the cholinergic nicotinic receptor genes (CHRNs) has 
repeatedly been found to be highly associated with nicotine dependence (see 35 for 
review). The first report of variants in nicotinic receptor genes contributing to nicotine 
dependence was a candidate gene study performed by members of our group 22,36. The 
most compelling association from that study was with a SNP near CHRNB3 on 
chromosome 8 in humans. However, they were also the first to report an association 
between the non-synonymous SNP rs16969968 (D398N in the a5 nicotinic receptor 
subunit gene). Despite big differences in the frequency of this SNP across populations, it 
shows a similar effect on risk, with odds ratios 1.3-2.00 in European, African American 
and Asian populations 37,38.  
 Notably, nicotinic receptor genes often form gene clusters. CHRNA5, CHRNA3 and 
CHRNB4 on chromosome 15 and CHRNA6 and CHRNB3 on chromosome 8 are directly 
adjacent to each other (Figure 1.6). This is of particular note, as at least some of these 
genes seem not to have evolved from tandem duplications, but rather most likely came 
together having been duplicated elsewhere to exist in close proximity on one haplotype 
block so that they could be co-regulated. If a phylogenetic tree is constructed using the 
amino acid sequences of all human nicotinic receptor paralogs, it is clear that the alpha 
subunits are more closely related to each other than to any beta subunit and that CHRNA3 
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shares more similarity to other alpha subunits than to CHRNA5, its closest physical 
neighbor (Figure 1.7). The hypothesis that these genes are co-regulated is confirmed in 
part when one considers the construction of “tabak” mice, constructed to possess a 
transgenic region encompassing all of the genes in the cluster, including non-coding 
regions 39. These mice overexpress chrnb4 and express an eGFP-chrna3 hybrid protein in 
precisely the regions of the brain that express the genes endogenously, suggesting that the 
surrounding non-coding DNA alone is sufficient to determine brain expression patterning.  
Since the discovery of the role of rs16969968 in nicotine dependence, multiple 
independent variants near the CHRNA5 gene have been identified that contribute to 
smoking related phenotypes.  The discovery of these variants was in part motivated by 
the presence of other nicotinic receptor genes in the region of association. A group of 
highly correlated variants including the SNP rs588765 near CHRNA5 was recently shown 
to increase CHRNA5 mRNA expression and increase risk of nicotine dependence 
independently of rs16969968 40,41. Additionally, a group of SNPs tagged by rs1996371 
near the CHRNB4 gene was shown to affect age of onset of daily smoking 42. Of note, 
this variant is not in high linkage disequilibrium (r2) with either the common non-
synonymous variant in CHRNA5 (rs16969968) or the variants correlated with CHRNA5 
mRNA (tagged by rs588765), suggesting as many as three independent associations 
between smoking related phenotypes and variants in this region. The common variants at 
the CHRNA6-CHRNB3 gene cluster as well as the common variants at the CHRNA5-
CHRNA3-CHRNB4 gene cluster tagged by rs16969968 were also recently shown to 
contribute to smoking quantity in several large meta-analysis genome-wide association 
studies 43,44. Together these results strongly suggest multiple mechanisms connecting 
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nicotinic receptor function to nicotine dependence and nicotine related behaviors. Despite 
these findings, only a small proportion of the variance (~5%) in nicotine dependence 
related traits has been explained by these variants 45. 
  The same genome-wide association study meta-analysis that identified variants in 
the CHRNA6-CHRNB3 and CHRNA5-CHRNA3-CHRNB4 gene clusters, also identified a 
group of variants near the CYP2A6 gene (tagged by rs4105144) that were genome-wide 
significantly associated with cigarette consumption 43. The CYP2A6 gene was an ideal 
candidate for such a study as it is the major hepatic nicotine-metabolizing enzyme in 
humans. There are several variants in or near CYP2A6 that reduce enzymatic activity and 
others that are highly associated with rate of nicotine metabolism 44,46. The GWA 
associated SNP is in LD with CYP2A6*2 (rs1801272) (r2 = 0.13 and D′ = 1.0 in the 
HapMap CEU samples) and the CYP2A6*2 reduced-function allele is only found on the 
background of the minor allele of rs4105144, associated with reduced smoking quantity. 
Further, our group has demonstrated that an allele defined by harboring a large deleted 
segment containing this SNP is also in complete LD (D’=1) with the GWA associated 
SNP. This not only suggests that the SNP rs4105144 is tagging several reduced-function 
variants, but that its association may have been partially exaggerated by having some 
hemizygous individuals who are heterozygous for rs4105144 appear as minor allele 
homozygotes.  
 
 Rare Variant Associations 
Rare genetic variants have recently been shown to contribute to a number of 
common human diseases (see 47 for review). Multiple rare variants have been reported in 
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genes previously shown to harbor common variants associated with common diseases 48-
50. Additionally, studies have demonstrated associations between rare variation in 
nicotinic receptor genes and nicotine dependence 51,52. As a class, rare SNPs, copy-
number variants (CNVs) and small insertion/deletion polymorphisms (indels) constitute 
the majority of human genetic variation and thus may hold the key to understanding part 
of the missing heritability of complex traits unaccounted for by recent genome-wide 
association studies. Sequencing is one of the few methods by which these variants can be 
investigated; however, the cost of sequencing hundreds or thousands of individuals for 
multiple genes remains high despite advances in sequencing technologies. An efficient 
alternative approach is to carry out DNA sequencing using DNA pooled from multiple 
individuals. Alternatively, whole exomes have recently become a relatively efficient 
method of performing gene-based, rare variant associations in an unbiased manner across 
the genome. This technique was first utilized for the identification of rare Mendelian 
diseases, but has recently expanded into gene-based genome-wide searches for common 
complex diseases. One of the first Mendelian disorders to be mapped using this method 
was Kabuki syndrome 4. The identification of the gene underlying this disorder was 
relatively straightforward, however, as it is recessive and thus required each affected 
individual to be either homozygous or a compound heterozygote for the same gene, a 
condition that is not met with high probability in the general population. Efforts have 
been far less successful for common complex, however, likely due to the limited power 
afforded by small sample size when using collapsed non-synonymous variants. Such 
variants are exceedingly rare, especially in genes with even moderate levels of cross-
species conservation, and as such require large sample sizes to obtain sufficient power to 
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detect an association. Candidate gene studies have had more success than whole-genome 
scans, likely due to the reduced burden of multiple testing. A study of five genes requires 
a modest p-value of 0.01 to reach statistical significance, while an exome sequencing 
study requires a p-value of 2.5x10-6 assuming 20,000 genes to reach statistical 
significance.  
 Methods for the analysis of multiple rare variants with regards to complex traits are 
still in their infancy. A number of studies have suggested strategies for investigating rare 
variants. Among these are the cohort allelic sums test  (CAST), combined multivariate 
and collapsing (CMC), weighted sum (WS), c-alpha, variable threshold (VT) and SKAT 
methods 9,53-55. Each technique combines multiple alleles to create aggregate genotypes, 
scores or linear models to be used in a test of association. In the case of the CAST 
method, the number of individuals with at least one mutation at a locus is compared in 
cases and controls. This is by far the simplest method, but has limitations. For the CMC 
method, rare variants are collapsed and then used with all common (≥5%) variants in a 
multivariate analysis. One of the more intriguing techniques developed thus far for 
detecting rare variant associations is the weighted sum method. In this method, variants 
are weighted in proportion to the inverse of their frequency and each weighted variant 
present in an individual is summed to form a person’s score. The scores of cases and 
controls are then compared by permutation. One aspect lacking in each of the 
aforementioned methods is some measure of the likelihood of functional impact for each 
of the variants used in the analysis. For instance, evolutionary conservation, regional 
genetic diversity or an actual measure of function for each variant would likely improve 
power if integrated into one of these analyses. One of the largest problems facing human 
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geneticists is how to determine what genetic variation present in a population is 
functional, in particular whether variants are functional with respect to the phenotype 
under study. The weighted sum method implicitly claims a relationship between variant 
frequency and the probability that the variant has functional consequences. This is a valid 
claim as far as sites under negative selection will tend to have reduced frequency 
compared to neutral sites. However, some variants are rare because they entered the 
population only a short time ago; they have not had sufficient time to be acted upon by 
either genetic drift or natural selection. A more direct estimate of a site's probability of 
function is its level of evolutionary conservation. Conservation is a proxy for functional 
constraint and the presence of negative selection. I have previously described a method 
using Tajima’s D, a measure of genetic diversity compared to divergence, to compare 
case and control allele frequency spectra at a locus 49. Another possibility would be to 
weight variants as in the weighted sum method but by likelihood ratio test (LRT) score, a 
measure of conservation, rather than by frequency 56. Recently, progress in the field of 
rare variant association testing was made with the introduction of the sequence kernel 
association test (SKAT) 55,57 and the c-alpha test 56. In the case of SKAT, the test is a 
score-based variance-component test that takes into account both rare and common 
variants. One limitation of collapsing methods is that if neutral common alleles are 
collapsed with even rare alleles with large effects, the common variant will mask the 
effects of the rare alleles. This is overcome at least in part by SKAT in that alleles are 
tested independently within the framework. For the c-alpha test, the distribution of allele 
frequencies is compared between cases and controls. Whether rare alleles occur more 
frequently in cases or controls, the distribution of alleles between cases and controls is 
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skewed and will be identified. Despite the success these methods have afforded 
researchers in the field, further work is necessary to perfect tests of rare variant 
association and improve our ability to detect these rare variants often with modest effect 
sizes. 
Recently, several groups have interrogated the contributions of rare genetic 
variants in select nicotinic receptor genes. Specifically, one group sequenced the 
CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNB2, 
CHRNB3, and CHRNB4 genes in ~1200 European Americans and another sequenced the 
CHRNA4 gene in ~200 ND cases and ~200 controls and the fifth exon of CHRNA4 in 
around 1000 additional ND cases and 1000 additional controls 51,52. Together, these 
groups were only able to observe modest associations between nicotine dependence and 
variants, either singly or collapsed across rare variants. They may have been limited by 
having used only European Americans, however, as African Americans are known to 
harbor a larger proportion of rare variation as they did not go though a recent population 
bottleneck. These results highlight the need for more thorough investigation of rare 
genetic variation in these nicotinic receptor genes with respect to susceptibility to 
nicotine dependence.  
 
Genetics of Alcohol and Cocaine Dependence 
Twin and adoption studies have suggested that in addition to genetic variants that 
contribute to risk of becoming dependent on a specific drug, there exist genetic factors 
underlying a generalized risk for becoming dependent on multiple substances (see 58 for 
review). Two such studies compared the rates of drug use for several commonly used 
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substances over time in a cohort of monozygotic (MZ) and dizygotic (DZ) twins, finding 
that the strong correlation observed between several drug dependence phenotypes could 
be accounted for in part by shared genetic factors 59,60. The findings suggest that there 
likely exist variants that contribute to risk for multiple drug dependence phenotypes 
independently and that it is therefore possible that variation in nicotinic receptor genes, 
despite having a clear mechanism of action with respect to nicotine dependence, may 
contribute to risk for other drug dependences.  
 Epidemiological studies have shown high levels of comorbidity among alcohol, 
cocaine and nicotine dependence 23. As such, it has been difficult to disentangle the 
effects of genetic variants on each of these phenotypes. Numerous studies have found that 
variants altering the function or expression of neuronal cholinergic nicotinic receptors 
(CHRNs) alter risk for becoming nicotine dependent and several have shown effects of 
variants in nicotinic receptors on risk for both alcohol and cocaine dependence (see 35 for 
review). It is unclear from some of these studies, however, how much of the association 
with a specific phenotype is due to the effect of the variant on nicotine versus alcohol or 
cocaine. Common single nucleotide polymorphisms (SNPs) in CHRNA5 and CHRNB3 
have been shown to be associated with nicotine dependence or nicotine consumption and 
the most strongly associated SNP in several GWAS of nicotine dependence, a non-
synonymous change (rs16969968/D398N) in CHRNA5, has been shown to also affect 
risk for cocaine dependence 61,62. Additionally, a highly correlated group of variants near 
CHRNA5 previously shown to alter CHRNA5 mRNA expression in vivo, alter risk for 
alcohol dependence 41. A group of common SNPs near the CHRNB3-CHRNA6 gene 
cluster were also shown to affect cigarette consumption in a recent GWAS 43. Together, 
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common variants explain only a small proportion of the variance (~1%) in alcohol or 
cocaine dependence 45. The Diagnostic and Statistical Manual of Mental Disorders 
Version IV (DSM-IV) is commonly used to assess and define alcohol dependence. The 
DSM-IV defines alcohol dependent cases as individuals who endorse three (or more) of 
the 7 symptoms of alcohol dependence at any time in the same 12-month period. Using 
these criteria, we and others have identified a number of loci across the genome either 
implicated in susceptibility to alcohol by linkage or by association. Among these are 
several variants in gamma-amino butyric acid receptors (GABRA), alcohol dehydrogenase 
(ADH), aldehyde dehydrogenase (ALDH), the mu opioid receptor (OPRM1) and bitter 
taste receptors (TAS) genes (see 63 for review). Only two loci have been implicated in 
alcohol dependence at the genome-wide significant level (< 5x10-8 ): A missense variant 
(rs1229984; R48H) in the ADH1B gene and a bin of common SNPs tagged by 
rs12912251 near C15orf53 64. Most of the other loci have only been weakly implicated as 
risk factors for alcohol dependence.  
 As for alcohol dependence, several candidate loci have been implicated in risk for 
cocaine dependence either by linkage or association studies 65-73. Among these are two 
opioid receptor genes (OPRM1 and OPRD1), genes involved in serotonin and dopamine 
systems like the 5-hydroxytryptamine (serotonin) receptor 1B gene (HTR1B) or the 
dopamine receptor D2 (DRD2), as well as a number of other candidate genes. Unlike 
alcohol dependence, no variant to date has been genome-wide significantly associated 
with cocaine dependence 74. This is because no genome-wide association study of 
cocaine dependence has been performed. Additionally, it is unclear how many of these 
genetic factors are contributing to cocaine dependence specifically or whether these 
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variants are affecting risk through their effects on susceptibility to other comorbid traits 
or on a generalized effect on drug dependence.   
 
Functional Studies of Nicotinic Receptors 
Neuronal nicotinic acetylcholine receptors are pentameric ion channels produced from 
various combinations of α and β receptor subunits and are the main target for nicotine in 
the brain (Figure 1.8-1.10). The vast majority of neuronally expressed nicotinic receptors 
contain the α4 and β2 subunits, but many other combinations are formed and have 
distinct properties and expression patterns. Figure 1.8 shows the distribution of various 
nicotinic receptor subunit combinations in the mouse brain. Many studies have 
interrogated the effects of altering either nicotinic receptor amino-acid sequence or 
expression level. Several nicotinic receptor genes have been characterized in mice by 
knocking out the gene or transgenic overexpression and several variants observed in 
human populations have been cloned and overexpressed to determine their effects using 
electrophysiological methods or calcium flux assays. To date, the Chrnb2, Chrnb4, 
Chnra6, Chrna4, Chrna7, Chrna3 and Chnra5 genes have been knocked out and the 
CHRNB4 gene has been overexpressed in mice 75. There are profound effects on nicotine-
induced behaviors in each case, strengthening the now well-established role of nicotinic 
receptors in determining the physiological effects of nicotine. The specifics regarding the 
role of each nicotinic receptor subunit are quite wide-ranging, however, though there are 
commonalities. For instance, both the deletion of Chrna5 and the deletion of Chrnb4 
results in resistance to nicotine induced seizures 76,77. At extremely high doses of nicotine, 
mice will enter an epileptic state. Mice lacking either of these genes can be administered 
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doses far exceeding the dose required to induce seizures in wild-type mice without 
noticeable effects. Many other drug related and behavioral changes are apparent in mice 
either lacking or overexpressing neuronal nicotinic receptor subunits. While knockout 
mice for β2, α4 or α6 nicotinic subunits did not self-administer nicotine, there is no 
difference between α7 knockout mice and wild-type as far as nicotine self-administration 
78-81. In contrast, mice lacking Chrna5 demonstrate enhanced nicotine self-administration 
39,77. With regard to drug independent behavioral changes, several nicotinic receptor 
knockout lines show differences from wild-type mice. For instance, locomotor behavior 
can be assessed in an open field test and can be categorized as being more navigational or 
more exploratory. Using this test, β2 knockouts show a shift toward navigation to the 
detriment of exploration 82. Re-expressing this subunit in the ventral tegmental area via 
lentiviral rescue was able to normalize this phenotype, suggesting the role of β2 subunits 
in this brain region in balancing these two aspects of locomotor behavior83,84.  
A number of in vitro studies of variants in nicotinic receptor genes have been 
performed in order to assess the functional impact of genetic variants on the receptors 
harboring them. The three major techniques for performing these assays are: 1) voltage-
clamp of HEK cells transiently or stably transfected with expression vectors containing 
wild-type or mutant nicotinic subunits, 2) voltage-clamp of xenopus oocytes injected with 
either wild-type or mutant mRNA and 3) calcium flux assays that utilize aequorin, a 
composite of the apoprotein apoaequorin and the prosthetic group coelenterazine, to 
assess agonist induced calcium influx. One such assay was used to demonstrate that 
receptors including the amino acid encoded by the minor/risk allele of the SNP 
rs16969968 (CHRNA5 D398N) show a reduced response to the nicotinic agonist, 
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epibatidine 85. These findings are in contrast, however, to results from whole-cell patch 
clamp of HEK293 cells stably expressing α3 and β4 nicotinic receptor subunits, 
transiently transfected with either the 398D or 398N form of the α5 nicotinic subunit 86. 
This study was not able to observe a significant difference between the normal and 
variant form of the receptor. Recent findings from our group have suggested that a high 
extra-cellular concentration of calcium is necessary to observe the effect, a condition met 
as a requirement of the experimental setup for the calcium flux assay used to demonstrate 
the functional effect of the SNP initially 87.  
Several variants in the CHRNB4 gene have been shown to affect receptor function 
using one of these in vitro assays 88. The CHRNB4 variants T91I, R136W, S140G, and 
M467V were each expressed heterologously in Xenopus oocytes and studied using the 
two-electrode voltage clamp. These experiments revealed that the 136W and 467V forms 
of the receptor had higher sensitivity to acetylcholine and lower EC50 than the wild-type. 
The T91I variant was shown to have lower sensitivity to acetylcholine and a larger EC50. 
Each of the T91I, R136W, and M467V variants also showed greater desensitization after 
long-term exposure to low-dose acetylcholine.  
One study of human carriers of the CHRNA5 D398N variant using resting-state 
functional MRI found that carriers of the 398N allele had decreased intrinsic resting 
connectivity strength in the dorsal anterior cingulate–ventral striatum/extended amygdala 
circuit 89. Though, as mentioned before, the vast majority of neuronally expressed 
nicotinic receptors contain the α4 and β2 subunits, many other combinations are formed 
and have distinct properties and expression patterns. It is thought that the various aspects 
of nicotine dependence (craving, withdrawal, tolerance, sensitivity, etc.) may be due to 
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these distinct characteristics. For example, recent studies have shown that mice lacking 
Chrna5 fail to display the adverse effects of high doses of nicotine and mice lacking 
Chrnb4 or Chrna5 show reduced somatic signs of withdrawal after ceasing long-term 
nicotine treatment 77,90. Additionally, mice over-expressing Chrnb4 were recently shown 
to display a strong aversion to nicotine, that can be reversed by virally mediated 
expression of α5 D398N variant in the medial habenula 39. This work suggests that the 
aversive effects of nicotine in mouse are regulated by the balanced activity of ß4 and α5 
nicotinic receptor subunits in the medial habenula. A recent association study of smoking 
cessation also suggests that variants in CHRNB4 may decrease craving and withdrawal 
symptoms 91.These findings suggest that multiple nicotinic receptor subunit genes likely 
play a role in the development and maintenance of nicotine dependence and that variants 
in these genes may have different and in some cases opposing functional effects in 
humans and mice. 
In addition to mediating the effects of nicotine, neuronal nicotinic receptors have 
also been shown to alter the cellular and behavioral effects of alcohol independently of 
nicotine 92-114. In vitro studies have shown altered response to ethanol upon perturbation 
of nicotinic receptors in neurons 95,106-108,115. Studies in rats have extensively shown that 
partial agonists of α4β2* or α3β4* nicotinic receptors affect alcohol consumption in vivo 
92,95-98,101-105. These results were confirmed and expanded using transgenic and knockout 
mice of various nicotinic receptor genes 93,94,109-114. Further, one recent human trial found 
that the α4β2 subunit partial agonist Varenicline was able to reduce alcohol consumption 
among smokers 116. Together these results suggest that altered nicotinic receptor function 
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likely has an effect on alcohol consumption independent of its effect on nicotine 
consumption. 
Conclusions 
Overall, work on the genetic basis of substance dependence, in this case nicotine, 
alcohol and cocaine dependence, has provided evidence that variants in the neuronally 
expressed nicotinic receptor genes can contribute to risk for these substance dependences. 
Work from many in the field has demonstrated that rare variation in genes may be able to 
explain a substantial proportion of the heritability still missing despite massive meta-
analysis efforts to uncover common variants underlying common disease. Together, these 
results suggest that interrogation of the role of rare coding variation in the neuronal 
nicotinic receptor genes will likely aid our understanding of the role of these genes in the 
etiology of substance dependence. In the following chapters, I will describe how we 
undertook sequencing of the most promising nicotinic receptor genes, those previously 
implicated by genome-wide association studies to be involved in nicotine dependence, to 
characterize the role of rare protein-altering variation in substance dependence risk. We 
hypothesize that rare variants in the 5 nicotinic receptor genes contained within the two 
gene clusters previously implicated in genome-wide associations studies, CHRNA5, 
CHRNB4, CHRNA3, CHRNA6 and CHRNB3, harbor rare coding variation associated 
with substance dependence, specifically nicotine, alcohol and cocaine dependence. 
Furthermore, as work to improve our ability to detect rare variant association has 
suggested that our ability to differentiate between protective, neutral and risk alleles will 
substantially improve our ability to both find and understand rare variant associations, I 
will describe how we functionally characterized all observed protein-altering variation in 
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CHRNB4 to investigate incorporating the observed functional impact of specific variants 
could improve our understanding of how these rare variants are affecting substance 
dependence risk.  We hypothesize that incorporation of such information will enhance 
our association signal.  
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Figure 1.1. Variance Explained at Differing uncorrected P-value Thresholds. Figure is 
take from 2. A) Studies using only the extremes of BMI B) Studies using BMI as a 
quantitative trait. Solid line is variance explained at each level of significance in the 
meta-analysis of all listed constituent studies.  
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Figure 1.2. Genomic Capture Strategy. Genomic DNA is prepared and hybridized with a 
library compared of biotinylated RNA complementary to regions of the genome to be 
captured. DNA-RNA hybrids are then incubated with streptavidin coated magnetic beads. 
All DNA not hybridized with the biotinylated-RNA is then washed away. The retained 
DNA is then amplified and sequenced.  Figure is taken from: 
http://www.genomics.agilent.com/.  
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Figure 1.3. Survival of men who either never smoked, are ex-smokers or smoked varying 
numbers of cigarettes per day on average. For example, ~65% of men who smoked ≥ 25 
cigarettes per day lived to be 65 years old. Figure is taken from 18. 
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Figure 1.4. Proportion of individuals transitioning from various steps in the progression 
to nicotine dependence. The heritabilities of the smoking initiation (left) and nicotine 
dependence (right) are shown in red. Dependence is based on the FTND scale. Data is 
from20,85.  
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Figure 1.5. Fagerström Test of Nicotine Dependence. Each question is worth 1 or 3 
points and the sum of the points assigned based on answers provided are summed to form 
a score from 1-10. A score above 4 confers a diagnosis of nicotine dependence 
Information is from 25,26.  
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Figure 1.6. Genomic context of sequenced genes. Positions are from human genome 
reference assembly build 36.1 (hg18). Direction of transcription is designated with an 
arrow. Exons are show as squares.  
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Figure 1.7. Phylogenetic tree of nicotinic receptor cDNA sequences. Two subunits are in 
a cluster on chromosome 8 (red) and three subunits form a cluster on chromosome 15 
(green). The most abundant subunit combination is highlighted in orange and muscle 
alpha and beta nicotinic receptor subunits are highlighted in blue. Figure was created 
using the ClustalW program 117.  
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Figure 1.8. Regional distribution of nicotinic acetylcholine receptors. (a) Subunit 
combinations were deduced either by binding, immunoprecipitation and/or 
immunopurification assays or from in situ hybridization, single-cell PCR and binding 
studies of tissues obtained from rat and/or wild-type and/or knockout mice. * refers to 
any of many possible subunits. Figure is taken from 118. 
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Figure 1.9. Cytisine resistant 125I-epibatidine binding. Slices of brains from mice 
overexpressing chrnb4 were incubated with cytosine and subsequently subjected to 125I-
epibatidine. Darker areas correspond to increased epibatidine binding not bound by 
unlabeled cytisine, which preferentially binds alpha4-beta4 containing receptors. Figure 
is taken from 39.  
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Figure 1.10. Nicotinic acetylcholine receptor configuration within the cell membrane 
(green). Subunits (red) form pentameric ion channels. Upon binding of acetylcholine 
(ACh) or other agonists, the pore is opened and the cell is depolarized. Binding of agonist 
(yellow circles) occurs at the interface between alpha and beta subunits in the case of 
heteromeric receptors. Figure is taken from 75. 
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Chapter 2. Identification of rare variants in cholinergic nicotinic receptor genes and 
their association with nicotine dependence2 
 
ABSTRACT 
Genome-wide association studies (GWAS) have identified common variation in the 
CHRNA5-CHRNA3-CHRNB4 and CHRNA6-CHRNB3 gene clusters that contribute to 
nicotine dependence. However, the role of rare variation in risk for nicotine dependence 
in these nicotinic receptor genes has not been studied. We undertook pooled sequencing 
of the coding regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, 
CHRNA6 and CHRNB3 genes in African American and European American nicotine 
dependent smokers and smokers without symptoms of dependence. Carrier status of 
individuals harboring rare missense variants at conserved sites in each of these genes was 
then compared in cases and controls to test for an association with nicotine dependence. 
We find a reduced risk for nicotine dependence among carriers of missense variants at 
conserved residues in CHRNB4 in African Americans and European Americans (AA p 
=0.0025, OR=0.31, 95% CI=0.31-0.72; EA p=0.023, OR=0.69, 95% CI=0.50-0.95). We 
note that given the possibility of stochastic differences in rare allele frequencies between 
groups replication is necessary to confirm these findings. 
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INTRODUCTION 
Genetic variation in the cholinergic nicotinic receptor genes (CHRNs) has repeatedly 
been found to be highly associated with nicotine dependence (see 35 for review). Multiple 
independent variants have been identified that contribute to smoking related phenotypes.  
Among these, the most strongly associated single nucleotide polymorphism (SNP) in 
several genome-wide association studies (GWAS) of nicotine dependence and correlated 
traits is a common non-synonymous change (rs16969968/D398N) in CHRNA5 43. Despite 
big differences in the frequency of this SNP across populations it shows a similar effect 
on risk, with odds ratios 1.3-2.0 in European, African American and Asian populations 
38,119. In vitro functional studies have demonstrated that receptors including the amino 
acid encoded by the minor allele, which is the risk allele, show a reduced response to the 
nicotine agonist, epibatidine 85. Human carriers of the minor allele show decreased 
intrinsic resting connectivity strength in the dorsal anterior cingulate–ventral 
striatum/extended amygdala circuit 89. Additionally, a group of highly correlated variants 
including the SNP rs588765 near CHRNA5 were shown to increase CHRNA5 mRNA 
expression and increase risk of nicotine dependence independently of rs16969968 41,45. 
Common variants at the CHRNA6-CHRNB3 gene cluster were also recently shown to 
contribute to smoking quantity 43. Together these results strongly suggest multiple 
mechanisms connecting nicotinic receptor function to nicotine dependence. Despite these 
findings, only a small proportion of the variance (~5%) in nicotine dependence related 
traits have been explained by these variants 45. Neuronal nicotinic acetylcholine receptors 
are pentameric ion channels produced from various combinations of α and β receptor 
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subunits and are the main target for nicotine in the brain. The vast majority of neuronally 
expressed nicotinic receptors contain the α4 and β2 subunits, but many other 
combinations are formed and have distinct properties and expression patterns. As such, it 
is thought that the various aspects of nicotine dependence (craving, withdrawal, tolerance, 
sensitivity, etc.) may be due to these distinct characteristics. For example, recent studies 
have shown that mice lacking Chrna5 fail to display the adverse effects of high doses of 
nicotine and mice lacking Chrnb4 or Chrna5 show reduced somatic signs of withdrawal 
after ceasing long-term nicotine treatment 77,90. Additionally, mice over-expressing 
Chrnb4 were recently shown to display a strong aversion to nicotine, that can be reversed 
by virally mediated expression of α5 D398N variant in the medial habenula 39. This work 
suggests that aversion of nicotine in mouse is regulated by the balanced activity of ß4 and 
α5 nicotinic receptor subunits in the medial habenula. A recent association study of 
smoking cessation also suggests that variants in CHRNB4 may decrease craving and 
withdrawal symptoms 91. These findings suggest that multiple nicotinic receptor subunit 
genes likely play a role in the development and maintenance of nicotine dependence and 
that variants in these genes may have different and in some cases opposing functional 
effects. 
Rare genetic variants have recently been shown to contribute to a number of common 
human diseases (see 47 for review). Specifically, multiple rare variants have been reported 
in genes previously shown to harbor common variants associated with common diseases 
48-50. Additionally, studies have demonstrated associations between rare variation in 
nicotinic receptor genes and nicotine dependence51,52. As a class, rare SNPs, copy-
number variants (CNVs) and small insertion/deletion polymorphisms (indels) constitute 
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the majority of human genetic variation and thus may hold the key to understanding part 
of the missing heritability of complex traits unaccounted for by recent genome-wide 
association studies. Sequencing is one of the few methods by which these variants can be 
investigated; however, the cost of sequencing hundreds or thousands of individuals for 
multiple genes remains high despite advances in sequencing technologies. An efficient 
alternative approach is to carry out DNA sequencing using DNA pooled from multiple 
individuals. To test the hypothesis that rare variants in the CHRNA5, CHRNA3, CHRNB4, 
CHRNA6 and CHRNB3 genes influence risk for nicotine dependence we have employed 
pooled sequencing in individuals with and without nicotine dependence in both European 
Americans and African Americans. We report that rare (<5%) missense variants at 
conserved sites in CHRNB4 are associated with decreased risk of developing nicotine 
dependence and decrease the number of cigarettes consumed daily by smokers.  These 
findings demonstrate that nicotine dependence is mediated by rare genetic variation and 
by variation in CHRNB4 specifically.   
 
METHODS 
Sample Selection 
DNA samples were collected as part of the Collaborative Genetic Study of Nicotine 
Dependence (COGEND). All members of the COGEND sample underwent a semi-
structured interview, which assessed smoking behavior, other substance use and 
comorbid psychiatric conditions. The COGEND sample includes 710 African Americans 
(461 nicotine dependent (ND) cases and 249 smokers with no symptoms of dependence 
(controls)) and 2055 European Americans (1062 ND cases and 993 controls). As these 
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individuals were ascertained to study nicotine dependence, Fagerström Test of Nicotine 
Dependence (FTND) scores (Range= 1-10) were required to be <1 for controls and >4 for 
cases. In all cases lifetime maximum FTND score was used. Additionally, to ensure that 
all individuals in the study had been exposed to nicotine, all members were required to 
have smoked at least 100 cigarettes in their lifetime. Among individuals with FTND 
scores >4, 96% (1458/1523) were also nicotine dependent using DSM-IV nicotine 
dependence criteria. A total of 352 African Americans (176 ND cases and 176 smoking 
controls) and 400 European Americans (200 ND cases and 200 smoking controls) were 
sequenced. For African Americans, pools of 88 individuals were used (2 case pools and 2 
control pools). For European Americans, pools of 200 were used (1 case pool and 1 
control pool). The case pools include individuals with FTND scores > 5 whereas the 
control pools include individuals with FTND scores <1. Individuals for case pools were 
chosen to select the most severely nicotine dependent subjects in our sample.  Follow up 
genotyping of SNPs identified and validated in the sequenced individuals was done in the 
remaining portion of the COGEND sample (310 African Americans and 1662 European 
Americans).  
Pooled Sequencing 
Pooled DNA sequencing was performed as previously described 120. A schematic of the 
technique can be seen in figure 2.1. The concentrations of individual DNA samples were 
first measured using Quant-iT™ PicoGreen reagent and pooled in equimolar amounts. 
Each pooled DNA sample was then used as the template for the amplification of each 
protein coding exon of the CHRNA3, CHRNA5, CHRNA6, CHRNB3 and CHRNB4 genes. 
Primers for the amplification of each exon were designed using Primer3 and reference 
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sequences were taken from the human genome reference assembly build 36.1 (hg18).  In 
order to ensure complete coverage of each desired exon, a minimum of 50 bp of flanking 
sequence on each side was required for each amplicon. We used Pfu high fidelity DNA 
polymerase in all PCR reactions to reduce the identification of SNPs generated as a result 
of the PCR (false positive SNPs). After PCR amplification of desired genomic regions, 
PCR products were cleaned using QIAquick PCR purification kits, quantified using 
Quant-iT PicoGreen reagent and ligated in equimolar amounts using T4 Ligase and T4 
Polynucleotide Kinase. At this stage, positive and negative control vectors were 
amplified and added to each pool to serve as internal quality standards and to be used in 
data analysis. After ligation, concatenated PCR products were randomly sheared by 
sonication and prepared for Illumina sequencing on an Illumina Genome Analyzer IIx 
(GAIIx) according to the manufacturers specifications. As previously shown by Vallania 
et al, 121 an average coverage of 30-fold per allele per pool was shown to correlate to 
optimal positive predictive value for the SNP-calling algorithm and was, therefore, the 
target level of coverage in this study. In order to obtain sufficient coverage per allele per 
pool, we obtained two lanes of Illumina GAIIx sequencing per pool. Coverage per 
amplicon was calculated for each pool after the first lane of sequence was obtained and 
only those amplicons not reaching 30-fold coverage per allele were included for the 
second lane of sequencing.  
Sequencing Analysis 
For analysis, sequencing reads (36 bp reads) were aligned using an alignment algorithm 
developed by Vallania et al. 121 which aligns sequences allowing for 2 mismatches or 
indels of up to 4 bp. In order to quantify the specificity and sensitivity of this method, 
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positive and negative control DNA were introduced as PCR products in the pooled 
sequencing protocol outlined above. As a positive control to estimate sensitivity for 
variant calling, a pool of 10 plasmids with a 72 bp insert was generated. One plasmid acts 
as the “wild-type” insert, while the remaining nine plasmids contain one or two 
synthetically engineered mutations. All ten plasmids were combined such that the allele 
frequency of each known mutation would mimic either the allele frequency of a single 
allelic variant or ten allelic variants in our human DNA pool. Following mixing of the 
vectors, PCR amplification across the insert sequence was performed and the PCR 
product was added to the normalized pool of human target PCR reactions during 
sequencing library preparation. We then obtained more coverage for each amplicon than 
that which was required to detect all variants in this amplified positive control vector pool 
in order to ensure a minimal SNP detection false negative rate. As a negative control and 
to model the sequencing error rate, 1908 bp of the pCMV6-XL5 plasmid were also 
amplified and included. One half of the pCMV6-XL5 plasmid sequence was used to train 
the SNP finding algorithm and the other to test the error model. Finally, to identify 
variants, in the pooled sequence data we used the SPLINTER algorithm 121. The 
SPLINTER algorithm produces a p-value for the probability that a predicted variant is a 
true positive. This probability is produced using large deviation theory to quantify the 
difference between observed allele frequencies within the sequence data to the 
background error rate for the same type of sequence changes seen in the amplified 
pCMV6-XL5 plasmid. The error model for one of the sequenced COGEND pools can 
been seen in figure 2.2. A p-value cut-off value for each lane of Illumina sequencing was 
defined as the value at which all positive controls were identified. Only those variants 
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falling below this cut-off value were considered “predicted” by SPLINTER. All protein 
coding or splice site variants predicted by SPLINTER were then validated by individual 
Sequenom genotyping in each person from the source DNA pools. SNPs validated in the 
sequenced individuals were then genotyped in all members of the COGEND sample. All 
individual genotyping was performed using the Sequenom platform as described 
previously 41.  
 
Association Analysis 
Each missense variant as well as the number of carriers of missense variants at conserved 
positions for each gene in the genes surveyed was tested for association with nicotine 
dependence in African Americans and European Americans using Fisher’s exact test. 
Conservation was determined by basewise vertebrate conservation using PhyloP score 122. 
A site was called conserved when its PhyloP score was greater than or equal to 2, 
corresponding to a p-value of 0.01.The SNP rs56218866 (CHRNB4 S140G) was 
excluded from analyses as it had been shown previously to have no measurable effect on 
receptor function and did not effect the significance of the association between CHRNB4 
carrier status and either nicotine dependence or CPD when taken as a covariate 88. For 
analysis of cigarettes per day (CPD), FTND score and withdrawal symptom count in 
carriers and non-carriers, Wilcoxon Rank-Sum tests were performed.  
 
RESULTS 
In order to identify novel rare variants associated with nicotine dependence, we 
sequenced 752 individuals from the extremes of the population distribution of FTND 
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scores in 6 pools. The protein coding regions of the 5 human cholinergic nicotinic 
receptor subunit genes constituting the gene clusters previously reported to harbor 
common variants associated with nicotine dependence (CHRNA5-CHRNA3-CHRNB4 
and CHRNA6-CHRNB3) were sequenced on an Illumina GAIIx and analyzed using the 
SPLINTER algorithm 121. We obtained greater than 30-fold coverage per allele at all 
positions within the 28 amplicons designed to cover the protein coding exons of 
CHRNA3, CHRNA5, CHRNA6, CHRNB3 and CHRNB4 and validated 24 (9 novel) 
missense variants (Figure 2.3 and Table 2.1). We only attempted to validate missense 
variants as these are more likely to have a functional impact than non-coding or 
synonymous coding changes. As the SPLINTER algorithm produces a p-value for the 
probability that a predicted variant is a true positive, we also genotyped a number of 
variants below our cut-off for significance in order to determine the positive predictive 
value of the algorithm. A total of 42 variants were genotyped in the sequenced 
individuals. Of these, 14 were selected for having probabilities of being true positives just 
below our cut-off value. Only 1 of these 14 variants was validated while 24 of 28 SNPs 
predicted to be true positives were validated. This produced a positive predictive value of 
86%. Additionally, all variants included as part of the amplified positive control vector 
were found upon achieving greater than 30-fold coverage at mutated sites (Sensitivity = 
100%) and only ~80 sites in the 1908 bp negative control vector were predicted to be 
polymorphic (Specificity = ~95%). The majority of validated variants, as expected, are 
rare (22/24 = 92% have MAF < 5%) in African Americans or Europeans. In fact, many 
are present in only one sequenced individual (7/24 = 29% are singletons). Additionally, 
some of the missense variants present in these genes were found at less conserved sites 
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(9/25; PhyloP score < 2), suggesting that they are less likely to have a functional impact. 
Altogether, we identified 15 variants (4 novel) at conserved sites and used these for 
further analysis. Of these, 12 were also predicted to be damaging by Polyphen, SIFT or 
both (Table 2.2) 123,124. We determined the frequency of each missense variant validated 
from sequencing in individuals from the Collaborative Study on the Genetics of Nicotine 
Dependence (COGEND) (710 African Americans and 2055 European Americans) using 
Sequenom. We then compared the frequency of each missense SNP as well as the 
number of carriers of conserved missense variants in cases and controls for each of the 
genes sequenced (Table 2.2). To ensure novel findings, we excluded the SNP rs16969968 
from analyses in European Americans as this would overshadow the effects of other 
variants in the CHRNA5 gene and because it is common in European Americans 
(Frequency= 0.35). We find that two SNPs in CHRNB4 (T91I and T375I) and one SNP in 
CHRNA3 (R37H) are associated with decreased risk of nicotine dependence either in 
African Americans or European Americans (Table 2.1). Notably, the T91I and R37H 
variants are in high linkage disequilibrium (LD) in European Americans (r2 =0.89, 
n=710) and African Americans (r2 =0.59, n=2035), making it difficult to determine the 
relative contribution of the two variants to the observed association. We found nominal 
evidence of association between rare variants at evolutionarily conserved sites and 
nicotine dependence at CHRNA5 in African Americans and CHRNA3 in European 
Americans.  
We find that carriers of rare missense variants at conserved sites in CHRNB4 were 
less frequently nicotine dependent compared to non-carriers, both in African Americans 
and European Americans (African Americans p = 0.0025, OR = 0.31, 95% CI = 0.31-
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0.72; European Americans p = 0.023, OR=0.69, 95% CI = 0.50-0.95) (Table 2.3). This is 
significant for African Americans after Bonferroni correction for multiple tests assuming 
one test for each gene studied (p < 0.01). As we are not able to distinguish between the 
effects of the T91I and R37H variants, carriers of missense variants at conserved sites in 
either CHRNA3 or CHRNB4 are also less frequently nicotine dependent compared to non-
carriers (African American p = 0.0035 European American p = 0.012). To determine if 
the observed association could be explained by the CHRNA3 R37H alone, we performed 
logistic regression including CHRNA3 R37H genotype as a covariate. CHRNB4 carrier 
status remained associated with nicotine dependence status in African Americans (p = 
0.0025), but not in European Americans (p=0.37). This is most likely because 
rs61737499 (CHRNB4 T375I), one of the major contributors to the association SNP in 
African Americans, is monomorphic in European Americans. Additionally, we 
investigated the possibility that one of the four comorbid DSM-IV defined substance 
dependence phenotypes measured in our dataset (alcohol, cocaine, marijuana and opiates) 
was contributing to the observed association at CHRNB4. None of these comorbid 
phenotypes significantly altered the association results observed between nicotine 
dependence and CHRNB4 carrier status in either African Americans or European 
Americans when included as a covariate in a logistic regression. These findings suggest 
that variants in CHRNB4 and possibly CHRNA3 protect against nicotine dependence and 
that this is not due to a correlation between nicotine dependence and other comorbid 
phenotypes. 
Two groups of common genetic variants within the CHRNA5-CHRNA3-CHRNB4 
gene cluster (tagged by rs16969968 and rs588765, respectively) were previously shown 
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to affect nicotine dependence risk. To determine if our findings could be due to LD with 
either of these variants, we performed logistic regression including each as a covariate. 
CHRNB4 carrier status remained associated with nicotine dependence status in African 
Americans (p = 0.0048), but not in European Americans (p=0.13) when rs16969968 
genotype was included as a covariate. However, we find that CHRNB4 carrier status is 
associated with nicotine dependence among carriers of the minor allele of rs16969968 
(Fisher’s exact test p=0.03, OR=0.55) in European Americans. CHRNB4 carrier status 
was associated with nicotine dependence status in African Americans (p = 0.0031) and in 
European Americans (p=0.043) when rs588765 genotype was included as a covariate. 
These findings suggest that our observed associations are not due to a correlation 
between rare variants in CHRNB4 and previously described common variant associations 
in the region.  
 To ensure that our findings within the African American portion of the COGEND 
sample is not due to population stratification, we calculated principal components using 
EIGENSTRAT 125. We then performed logistic regression to test the association between 
CHRNB4 carrier status at conserved sites and nicotine dependence including the first two 
principal components (PC1 and PC2) as covariates. CHRNB4 carrier status remained 
associated with nicotine dependence status in African Americans (p = 0.0038). 
Additionally, we calculated local admixture using LAMP 126. CHRNB4 carrier status 
remained significantly associated with nicotine dependence when we performed logistic 
regression including local admixture estimates from the 100kb encompassing the 
CHRNA5-CHRNA3-CHRNB4 gene cluster as a covariate (p = 0.0029). These findings 
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suggest that the observed association is not due to population stratification, either on a 
genome scale or on a local scale.  
In order to examine which aspects of nicotine dependence are affected by variants 
in CHRNB4, we tested the association between several nicotine related phenotypes in 
addition to case status. When we compared the distribution of CPD in CHRNB4 
conserved SNP carriers and non-carriers, we observed that carriers also have a lower 
mean CPD than non-carriers (African American p = 6.6x10-5, European American p = 
0.021) (Figure 2.4).  FTND as a quantitative trait was also lower in carriers compared to 
non-carriers (African American p = 0.0019, European American p = 0.008) (Table 2.3). 
Using DSM-IV criteria to assign nicotine dependence case status we find carriers to have 
reduced risk of becoming nicotine dependent in African Americans (p = 0.03) and 
European Americans (p = 0.02). As Chrnb4 knockout mice exhibit reduced withdrawal 
symptoms upon cessation of prolonged nicotine exposure 90,127, we investigated whether 
conserved missense variants in CHRNB4 contribute to withdrawal symptoms among 
individuals who attempt cessation.  We find carriers of conserved missense variants in 
CHRNB4 show fewer signs of withdrawal as measured by the number of withdrawal 
symptoms endorsed in African Americans but not European Americans (African 
American p = 0.012, European American p = 0.42) (Table 2.3).  
 
 
DISCUSSION 
 We find that rare missense variants at evolutionarily conserved sites in CHRNB4 
and CHRNA3 protect against nicotine dependence in African Americans and European 
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Americans. We do not find an association between rare variants, conserved or otherwise, 
and nicotine dependence at the other genes studied (CHRNB3, CHRNA6 and CHRNA5) 
in African Americans or European Americans. This may be due to insufficient power 
resulting from low minor allele frequencies even after collapsing genotypes within genes. 
For instance, the frequency of carriers of missense variants at conserved loci for 
CHRNA5 in European Americans is 0.015 while the frequency of such carriers for 
CHRNB4 is 0.055. This increased carrier frequency for CHRNB4 was in large part due to 
the combined frequency of the two variants (T375I and T91I) which is why we chose to 
study these SNPs in vitro (see chapter 4). It is important to note that rare variant 
associations are more dependent on stochastic events, namely the sampling of rare allele 
carriers from a population, than studies of common genetic variants. It is possible that our 
observed associations may be due to chance fluctuations in rare variant allele. 
 When considering genetic associations in admixed populations, it is important to 
insure that findings are not due to subtle population stratification, either on a genome 
scale or locally at associated loci. As a result, we calculated both global and local 
measures of admixture for each of the African American individuals in COGEND. We 
find that neither global nor local admixture is able to account for the association we 
observe between rare missense variants at evolutionarily conserved sites in CHRNB4 and 
nicotine dependence.  
 In addition to nicotine dependence, we examined the effect of conserved missense 
variants in CHRNB4 on several phenotypes designed to tease apart various aspects of 
dependence. Specifically, we find that African American and European American rare 
variant carriers smoke fewer cigarettes per day (CPD) and that African American carriers 
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experience fewer withdrawal symptoms when compared to non-carriers. These data 
suggest that these CHRNB4 variants are likely contributing to the risk of developing 
nicotine dependence by allowing carriers to quit more easily, possibly by allowing them 
to smoke fewer cigarettes per day to combat withdrawal symptoms. It is difficult to 
determine with confidence which aspect of nicotine dependence variants in CHRNB4 are 
affecting, however, as each of the phenotypes analyzed are highly correlated in our 
sample (r2 from 0.32-0.85) and because our sample was selected to contain the extremes 
of the population distribution of FTND score.  These findings are in contrast to those of 
Wessel et al. who found no association between CHRNB4 variants and nicotine 
dependence 51. This lack of association on their part, however, was likely due to lack of 
power (they sequenced on 448 individuals) and our association is strongest in African 
Americans, a population not sequenced at these genes previously by any group.  
 In conclusion, we find an excess of conserved missense variants in CHRNB4 in 
smokers who are not nicotine dependent compared to smokers who are nicotine 
dependent. We hypothesize that these variants act by increasing sensitivity to nicotine 
and that these changes lead to our overall finding of decreased risk for nicotine 
dependence. Further sequencing of individuals for whom detailed dependence related 
information has been obtained is necessary to confirm and elaborate on these findings.  
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Figure 2.1. Pooled Sequencing Scheme for COGEND. DNA was quantified and pooled. 
The exons and flanking regions for the listed genes were amplified by PCR using PFU 
high-fidelity polymerase, pooled and sequenced on an Illumina GAIIx.   
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Figure 2.2. Representative Error Model for COGEND Pools. Each line is the average rate 
of change of each nucleotide changing to each of the other possible nucleotides for each 
of the possible positions within the Illumina sequencing read. Error rates increase 
dramatically after 30 cycles as a result of the chemistry used.  
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Figure 2.3. Schematics of the CHRN genes studied and the locations of missense variants 
identified in sequenced individuals from the COGEND study. Each protein consists of a 
signal peptide, two extracellular domains, four transmembrane domains (TM1-4) and 
three intracellular domains. Conserved sites (phyloP44Vertebrate score > 2) are shown in 
grey, while all others are shown in black. 
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Figure 1. Schematics of the CHRN genes studied and the locations of missense 
variants identified in sequenced individuals from the COGA study. Each protein 
consists of a signal peptide (green), two extracell lar domains, (blue) four 
tran membrane domains (TM1-4) and three intracellular domains (blue). Conserved 
sites (phyloP44Vertebrate score > 2) are shown in red, while ll others are shown in
black. 
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Figure 2.4. Average number of cigarettes smoked per day (CPD) for carriers and non-
carriers of missense variants at evolutionarily conserved sites in African Americans and 
European Americans. *** = 6.6x10-5;  * = 0.021 
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Chapter 3. Identification of rare variants in cholinergic nicotinic receptor genes and 
their association with alcohol and cocaine dependence3 
 
ABSTRACT 
Previous findings have demonstrated that variants in nicotinic receptor genes are 
associated with nicotine, alcohol and cocaine dependence. Because of the substantial 
comorbidity, it has often been unclear whether a variant is associated with multiple 
substances or whether the association is actually with a single substance. In order to 
investigate the possible contribution of rare variants to the development of substance 
dependencies other than nicotine dependence, specifically alcohol and cocaine 
dependence, we undertook pooled sequencing of the coding regions and flanking 
sequence of CHRNA5, CHRNA3, CHRNB4, CHRNA6 and CHRNB3 in 287 African 
American and 1028 European American individuals from the Collaborative Study of the 
Genetics of Alcoholism (COGA). All members of families for whom any individual was 
sequenced (2504 African Americans and 7318 European Americans) were then 
genotyped for all variants identified by sequencing. For each gene, we then tested for 
association using FamSKAT, which incorporates family structure using a kinship matrix. 
For European Americans, we find increased DSM-IV cocaine dependence symptoms 
(FamSKAT p =2x10-4) and increased DSM-IV alcohol dependence symptoms 
(FamSKAT p=5x10-4) among carriers of missense variants in CHRNB3. Additionally, 
one variant (rs149775276; H329Y) shows association both with cocaine dependence 
symptoms (p=7.4x10-5, β=2.04) and alcohol dependence symptoms (p=2.6x10-4, β=2.04) 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  Portions	  of	  this	  chapter	  are	  adapted	  from:	  Haller,	  G.,	  Kapoor,	  M.,	  et	  al.	  Rare missense 
variants in CHRNB3 and CHRNA3 are associated with risk of alcohol and cocaine 
dependence (submitted)	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when analyzed alone. For African Americans, we find decreased cocaine dependence 
symptoms among carriers of missense variants in CHRNA3 (FamSKAT p=0.006).  These 
are the first results to implicate rare variants in CHRNB3 or CHRNA3 in risk for alcohol 
dependence or cocaine dependence. 
INTRODUCTION 
Twin and adoption studies have suggested that in addition to genetic variants that 
contribute to the risk of becoming dependent on a specific drug, there exist genetic 
factors underlying a generalized risk for becoming dependent on multiple substances (see 
58 for review, 59,60). Epidemiological studies have shown high levels of comorbidity 
among alcohol, cocaine and nicotine dependence 128,129. Because of the substantial 
comorbidity, it is often unclear whether a variant is associated with multiple substances 
or whether the association is actually with a single substance but the extensive 
comorbidity leads to apparent association with other substances. Numerous studies have 
found that variants altering the function or expression of neuronal cholinergic nicotinic 
receptors (CHRNs) alter risk for becoming nicotine dependent and several have shown 
effects of variants in nicotinic receptors on risk for both alcohol and cocaine dependence 
(see 35 for review). Common single nucleotide polymorphisms (SNPs) in CHRNA5 and 
CHRNB3 are associated with nicotine dependence or cigarette consumption 43,130. The 
most strongly associated SNP in several GWAS of nicotine dependence, a non-
synonymous change (rs16969968/D398N) in CHRNA5, has also been shown to mitigate 
risk for cocaine dependence 61,62. Additionally, a highly correlated group of variants near 
CHRNA5, previously shown to alter CHRNA5 mRNA expression in vivo, have been 
reported to alter risk for alcohol dependence 41 in addition to nicotine dependence 131. 
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GWAS of cigarette consumption has also implicated a group of common SNPs near the 
CHRNB3-CHRNA6 gene cluster 43 that have been suggested to be involved in alcohol 
consumption, although not with cocaine related behaviors 132. In addition to mediating the 
effects of nicotine, neuronal nicotinic receptors have also been shown to alter the cellular 
and behavioral effects of alcohol and cocaine independently of nicotine 92-94,97-114. 
Evidence from in vitro studies indicates altered response to ethanol upon perturbation of 
nicotinic receptors in neurons 95,106-108,115. Studies in rats have shown that partial agonists 
of α4β2* or α3β4* nicotinic receptors affect alcohol consumption in vivo 92,95-98,101-105. 
These results were confirmed and expanded using transgenic and knockout mice for 
various nicotinic receptor genes 93,94,109-114. The physiological and behavioral effects of 
cocaine are also dependent on nicotinic receptors. Studies in mice, rats and non-human 
primates have suggested that cocaine administration alters nicotinic receptor expression 
and in so doing leads to altered response to cocaine 133-136. A recent human trial also 
found that the α4β2 subunit partial agonist Varenicline reduced alcohol consumption 
among smokers 116. Together these results suggest that altered nicotinic receptor 
expression and function likely has an effect on alcohol and cocaine consumption 
independent of its effect on nicotine consumption.  However, despite the promising 
evidence of synergy and cross-substance influences, the combined effects of discovered 
common variants have explained only a small proportion of the variance (~5%) in 
nicotine dependence and even less of the variance in alcohol or cocaine dependence 45. 
Rare variants may explain much of the unexplained heritability of these complex 
substance use disorders. 
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As a class, rare variants constitute the majority of genetic variation. A recent 
survey of more than 4000 exomes from individuals of European and African descent 
showed that as much as 86% of coding variants have a frequency less than 0.05% and 
that these rare variants are 4 times as likely to be deleterious 137. Many examples now 
exist of rare variants contributing to common human diseases (see 47 for review), both in 
genes previously reported to cause Mendelian forms of disease and in genes harboring 
common SNP associations 48-50. Several studies have demonstrated associations between 
rare variation in nicotinic receptor genes and nicotine dependence 51,52,138. An efficient 
method of determining the full spectrum of genetic variation in a region and thus the 
relative contribution of rare genetic variation to a trait of interest is to sequence pools of 
DNA from multiple individuals and to use statistical methods to determine which sites 
are polymorphic and at what frequency. We have employed this approach to determine 
the contribution of rare non-synonymous variants in the CHRNA5, CHRNA3, CHRNB4, 
CHRNA6 and CHRNB3 genes to alcohol and cocaine dependence. My aim in this chapter 
is to investigate the hypothesis that rare missense variants in nicotinic acetylcholine 
receptor genes contribute in aggregate to risk for alcohol and/or cocaine dependence 
independently of nicotine dependence.  
 
METHODS 
Sample Selection 
COGA Sample  
DNA samples were collected as part of the Collaborative Study of the Genetics of 
Alcoholism (COGA). All members of the COGA sample underwent a semi-structured 
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interview, the SSAGA, which assessed alcohol, cocaine and nicotine use as well as 
comorbid psychiatric conditions. The COGA sample utilized in this study consisted of 
2504 African Americans and 7318 European Americans. Maximum lifetime cigarettes 
per day (CPD) was used as a covariate in all analyses. CPD was calculated by comparing 
reports across multiple interviews for an individual and selecting the value of cigarettes 
smoked per day that reflected the largest number smoked during the time when the 
subject was smoking the most. Only individuals who had at one point in their life smoked 
have CPD values. Controls consisted of individuals who had tried a substance but never 
became dependent. A total of 287 African American (147 cases and 140 controls) and 
1028 European American (480 cases and 548 controls) individuals were sequenced. For 
African Americans, pools ranging in size from 44-96 individuals were used (2 case pools 
and 2 control pools). For European Americans, pools ranging in size from 68-96 
individuals were used (5 case pools and 6 control pools). Follow up genotyping of SNPs 
identified and validated in the sequenced individuals was done in the remaining members 
of each family represented in the sequenced set of individuals (2217 African Americans 
and 6290 European Americans).  
 
COGEND Sample 
DNA samples were collected as part of the Collaborative Genetic Study of Nicotine 
Dependence (COGEND). All members of the COGEND sample underwent a semi-
structured interview, which assessed smoking behavior, other substance use and 
comorbid psychiatric conditions. The COGEND sample includes 710 African Americans 
and 2055 European Americans. The coding regions of the CHRNA3, CHRNB4, CHRNA5, 
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CHRNB3 and CHRNA6 genes were sequenced in a total of 352 African Americans (176 
ND cases and 176 smoking controls) and 400 European Americans (200 ND cases and 
200 smoking controls). Of these sequenced individuals, 120 (34%) of the African 
Americans had non-zero DSM-IV alcohol dependence symptom counts, 300 (75%) of the 
European Americans had non-zero DSM-IV alcohol dependence symptom counts, 23 
(6.5%) of the African Americans had non-zero DSM-IV cocaine dependence symptom 
counts and 50 (12.5%) of the European Americans had non-zero DSM-IV cocaine 
dependence symptom counts.  All missense variants observed in these sequenced genes 
were genotyped in all members of COGEND using Sequenom.  
 
Pooled Sequencing 
Pooled DNA sequencing was performed as previously described 120,121,138. A schematic of 
the sequencing technique used can be seen in figure 3.1. A representative error model for 
one of the lanes of sequencing produced for this study can be seen in figure 3.2. As 
previously shown by Vallania et al, 121 an average coverage of 30-fold per allele per pool 
was shown to correlate to optimal positive predictive value for the SNP-calling algorithm 
and was, therefore, the target level of coverage in this study.  
 
Sequencing Analysis 
For analysis, sequencing reads (36bp reads) were aligned using an alignment algorithm 
developed by Vallania et al. 121 which aligns sequences allowing for 2 mismatches or 
indels of up to 4 bp. Positive and negative control DNAs were introduced as previously 
described 138. To identify variants in the pooled sequence data we used the SPLINTER 
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algorithm 121. All protein coding or splice site variants predicted by SPLINTER were 
validated by individual Sequenom genotyping in each person from the source DNA pools. 
SNPs validated in the sequenced individuals were then genotyped in all members of the 
COGA sample. All individual genotyping was performed using the Sequenom platform 
as described previously 139.  
 
Association Analysis 
Single missense variants were tested for association in African Americans and European 
Americans from the COGA study using linear regression as implemented in the GWAF 
package in R using age, sex and CPD as covariates. Each sequenced gene was tested as a 
whole for association using famSKAT using age, sex and CPD as covariates.  The 
GWAF and famSKAT programs were used as the COGA study is family-based and 
requires programs that can integrate family information. Associations in COGEND 
between alcohol dependence symptom count or cocaine dependence symptom count and 
variants in the CHRNB3 or CHRNA3 genes were performed using linear regression in 
PLINK using age, sex and CPD as covariates and in R comparing the residuals of alcohol 
or cocaine dependence symptom count after correcting for age, sex and CPD in CHRNB3 
missense variant carriers vs. non-carriers and CHRNA3 missense variant carriers vs. non-
carriers using a Wilcoxon Rank Sum Test. Linear regression and Wilcoxon Rank-Sum 
tests were used as COGEND is a sample of unrelated cases and controls.  
 
RESULTS 
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We sequenced the protein coding regions of the 5 human cholinergic nicotinic 
receptor subunit genes constituting the gene clusters previously reported to harbor 
common variants associated with nicotine dependence (CHRNA5-CHRNA3-CHRNB4 
and CHRNA6-CHRNB3) in 287 unrelated African Americans (147 DSM-IV alcohol 
dependent cases and 140 controls) and 1028 unrelated European Americans (480 DSM-
IV alcohol dependent cases and 548 controls) as part of the Collaborative Study of the 
Genetics of Alcoholism (COGA). DNA pools were sequenced on an Illumina GAIIx and 
analyzed using the SPLINTER algorithm 121. In total, we validated 31 non-synonymous 
variants (Figure 3.3 and Table 3.1). Of these, all but rs16969968 were rare (<5% MAF), 9 
(29%) were novel and 15 (48%) were present in only one sequenced individual. All 
variants included as part of the amplified positive control vector were found upon 
achieving greater than 30-fold coverage at mutated sites (Sensitivity = 100%) and only 63 
sites in the 1908 bp negative control vector were predicted to be polymorphic (Specificity 
= ~97%).  
 We genotyped each missense variant validated from sequencing in every 
individual from the COGA study for whom DNA existed, totaling 2504 African 
Americans and 7318 European Americans. We then tested for association between non-
synonymous variant carrier status at each sequenced gene and either alcohol or cocaine 
dependence symptom count using the family-based Sequence Kernel Association Test 
(FamSKAT), which incorporates relatedness into the model using a kinship matrix.  Age, 
sex and the number of cigarettes smoked per day (CPD) were included in the model as 
covariates. To increase the chances of novel findings, we did not include the SNP 
rs16969968 in analyses of European Americans or African Americans as it might 
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overshadow the effects of other variants in the CHRNA5 gene and because it is common 
in European Americans (Frequency= 0.35). 
Analysis of European Americans 
For European Americans, we find increased DSM-IV alcohol dependence 
symptoms (1.3 ± 2.5 vs. 0.65 ± 1.8, famSKAT p= 5x10-4) and increased DSM-IV cocaine 
dependence symptoms (2.27 ± 2.7 vs. 2.07 ± 2.4, famSKAT p =2x10-4) among carriers of 
missense variants in CHRNB3 (Table 3.2 and Figure 3.4).  Further, among the SNPs 
comprising the CHRNB3 carrier genotype (S326T, H329Y, K451E and V368M), one 
variant (rs149775276; H329Y) was significantly associated in a linear regression model 
with increases in both cocaine dependence symptoms (p= 7.4x10-5, β=2.04) and alcohol 
dependence symptoms (p= 2.6x10-4, β=2.04) (Figure 3.4). We also tested each gene for 
association with CPD using famSKAT and found no significant associations between 
CPD and rare missense variants at any of the genes sequenced in this dataset, suggesting 
that this is a direct effect of these variants on risk for alcohol and cocaine dependence 
phenotypes.  
In order to determine if these findings were the result of a correlation between 
alcohol or cocaine symptom count and smoking (Figure 3.5 and Figure 3.7), which had 
not been accounted for using CPD as a covariate, we tested whether these associations 
remained when only heavy smokers (CPD ≥20) were analyzed, as there is no significant 
correlation between alcohol symptom count or cocaine symptom count and CPD among 
these heavy smoking individuals. Using only heavy smokers (N=2509), the association 
between CHRNB3 and alcohol symptom count (famSKAT p = 0.0064) and cocaine 
dependence symptom count (famSKAT p = 0.002) remained significant, although 
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reduced. No associations between carrier status at any sequenced gene and alcohol or 
cocaine symptom count were observed in non-smokers (N=3177). Despite large numbers 
of non-smokers, very few non-smokers are alcohol dependent (N=387; 12%) or cocaine 
dependent (N=73; 2%), greatly reducing power to detect associations with these 
phenotypes in this subset of individuals. Overall, these analyses suggest that rare 
CHRNB3 variants are associated with cocaine dependence symptoms and alcohol 
dependence symptoms and that these associations cannot be fully explained by comorbid 
smoking behavior.  
As expected, there are high rates of comorbidity between cocaine dependence and 
alcohol dependence in our sample (Figure 3.6). For example, only 3% of European 
cocaine dependent cases and ~5% of African Americans cocaine dependent cases in our 
sample have no symptoms of alcohol dependence. To determine if the observed 
association in European Americans between CHRNB3 variants and either cocaine 
dependence symptoms or alcohol dependence symptoms could be explained by a 
correlation between the two phenotypes, we included alcohol dependence symptom count 
as a covariate in the analysis of cocaine dependence and vice versa. The association 
between cocaine dependence symptoms and both CHRNB3 (famSKAT p=0.009) and 
rs149775276 (linear regression p =0.002) remained significant when alcohol dependence 
was used as a covariate. Using cocaine dependence symptom count as a covariate, 
however, CHRNB3 carrier status did not remain significantly associated with alcohol 
dependence symptoms (famSKAT p = 0.66). These findings suggest that variants in 
CHRNB3 increase risk for cocaine dependence, but only increase risk for alcohol 
dependence indirectly by increasing risk for cocaine dependence symptoms or that the 
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structure of the dataset is such that one cannot correct for cocaine dependence symptoms 
without disrupting all associations with alcohol dependence symptoms. One group of 
common SNPs within the CHRNB3-CHRNA6 gene cluster (tagged in our dataset by 
rs6474412) was previously shown to affect levels of nicotine consumption and nicotine 
dependence 36,43,140. To determine if our findings in CHRNB3 could be due to linkage 
disequilibrium (LD) with this variant, we tested for association between rs6474412 and 
both alcohol and cocaine dependence symptom count, but in neither case was a 
significant association observed. (alcohol symptom count p =0.49, β=-0.03; cocaine 
symptom count: p =0.91, β=-0.01). This suggests that our observed associations are not 
due to a correlation between rare variants in CHRNB3 and the previously described 
common variant.  
 
Analysis of African Americans 
For African Americans, we found decreased DSM-IV cocaine dependence 
symptoms among carriers of missense variants in CHRNA3 (famSKAT p= 0.006) 
(Table3.3). As for European Americans, age, sex and CPD were included as covariates in 
the analysis. As there were only two missense variants observed in CHRNA3 in African 
Americans, this association was due largely to the association between cocaine 
dependence symptoms and one variant (rs8192475; R37H). This variant was previously 
shown to decrease risk for nicotine dependence and increase cellular response to nicotine 
in vitro 138. The association between CHRNA3 carrier status and cocaine dependence 
symptom count remained significant even after alcohol dependence symptoms was 
included as a covariate (famSKAT p =0.04). 
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To determine if our findings in African Americans could be explained by subtle 
population stratification, we calculated principal components using EIGENSTRAT125 and 
included the first two principal components (PC1 and PC2) as covariates in the linear 
regression. CHRNA3 carrier status remained associated with cocaine dependence 
symptom count in African Americans (famSKAT p= 0.01). No sequenced gene other 
than CHRNA3 was significant before or after addition of the first two principal 
components as covariates in the analysis. Additionally, we calculated local admixture 
using LAMP 126. CHRNA3 carrier status remained significantly associated with cocaine 
dependence symptoms when we performed linear regression including local admixture 
estimates from the 100kb encompassing the CHRNA5-CHRNA3-CHRNB4 gene cluster as 
a covariate (famSKAT p= 0.03).  No sequenced gene other than CHRNA3 was significant 
before or after addition of estimated local ancestry as a covariate in the analysis. These 
findings suggest that the observed association is not due to population stratification, 
either on a genome or a local scale.  
Replication in COGEND 
 Previous findings from the Collaborative Genetic Study of Nicotine Dependence 
(COGEND) have suggested that rare variants in CHRNB4 reduce risk of nicotine 
dependence 138. Using previously obtained sequencing data from COGEND 138, we aimed 
to determine whether we could replicate the findings from COGA. We tested for 
association between alcohol dependence symptom count and cocaine dependence 
symptom count and variants in the CHRNB3 and CHRNA3 genes in the COGEND 
sample. We used both linear regression and a non-parametric Wilcoxon Rank Sum test as 
appropriate for this sample of unrelated subjects. Linear regression using age, sex and 
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CPD as covariates revealed that, among African Americans, variants in CHRNB3 are 
associated with increased alcohol dependence symptoms (p= 0.004, β=0.48) (Table 3.5). 
This was then confirmed using a Wilcoxon Rank Sum test comparing the distribution of 
age, sex and CPD corrected alcohol symptom count in CHRNB3 carriers vs. non-carriers 
(p= 0.006). There was no association between either alcohol or cocaine symptom count 
and CHRNA3 variants among African Americans. More than 60% (N=1685) of 
individuals in the COGEND sample have ≥ 1 alcohol dependence symptom, but there is a 
severe lack of power to interrogate cocaine dependence symptoms in COGEND because 
only ~10% (N=290) of individuals in this dataset have non-zero cocaine dependence 
symptoms. We observed no association between either CHRNB3 or CHRNA3 and 
cocaine dependence symptoms in European Americans from the COGEND study (Table 
3.4).  
DISCUSSION 
 We find that rare missense variants in CHRNB3 are associated with increased risk 
for cocaine dependence and alcohol dependence among European Americans and that 
rare missense variants in CHRNA3 are associated with decreased risk of cocaine 
dependence among African Americans. Upon including comorbid substance 
dependencies or proxies thereof (i.e. CPD for nicotine dependence) as covariates, we find 
that the observed association with cocaine dependence symptom count remains, 
suggesting that this association is not due to correlations between any of the other studied 
substances, but that the association between variants in CHRNB3 and alcohol dependence 
symptoms among European Americans may reflect the correlation of this trait with 
cocaine dependence symptoms in the COGA dataset.  
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 The association between CHRNB3 and both alcohol and cocaine dependence was 
largely due to one variant (rs149775276; H329Y). This variant was rare in European  
Americans, but absent in African Americans, partially explaining the lack of association 
at this gene among African Americans in the COGA dataset.  We were able to replicate 
the association between CHRNB3 and alcohol dependence in the COGEND African-
American sample.  It is likely that we were able to observe an association between 
CHRNB3 variants and alcohol dependence symptoms but not cocaine dependence 
symptoms in COGEND because alcohol dependence symptoms appear more often among 
COGEND individuals (~60%) than do cocaine dependence symptoms (~10%). 
Additionally, this association was only observed among African Americans individuals in 
COGEND. The frequency of CHRNB3 carriers among COGEND European Americans 
was exceedingly small (0.6% of individuals) compared to CHRNB3 carriers among 
African Americans (~4%).   
 The association between CHRNA3 and cocaine dependence among African 
Americans was due almost entirely to the effect of one variant (R37H; rs8192475). This 
variant was previously shown to decrease risk for nicotine dependence and increase 
cellular response to nicotine in vitro. Because CHRNA3 R37H is rarer in African 
Americans (~0.1%) than European Americans (~4%), the absence of association among 
European Americans is not likely to be due to lack of power. However, there may be an 
effect of differing genetic background between the two ethnic groups that cannot be 
accounted for in our analyses.  Additionally, controlling for both global and local 
admixture in the African American cohort does not affect the association observed 
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between CHRNA3 and cocaine dependence symptom counts, suggesting that this 
association is not due to population stratification, however subtle.  
For the other genes studied (CHRNB4, CHRNA6 and CHRNA5), no associations 
were observed between rare variants and either alcohol or cocaine dependence in 
European Americans or African Americans. This may have been due to insufficient 
power resulting from low minor allele frequencies even after collapsing genotypes within 
genes. Rare variant associations are more dependent on chance observation, namely the 
sampling of rare allele carriers from a population, than studies of common genetic 
variants. It is possible that our observed associations may be due to chance fluctuations in 
rare variant alleles. 
There is a debate in the scientific community regarding the relative role of 
common versus rare genetic variants in determining an individual’s risk of developing 
common diseases. Whether or not the majority of variability in any given trait will 
eventually be attributed to common or rare variants is yet to be determined. However, this 
and other studies continue to demonstrate the power of rare variant association testing in 
the identification and validation of genes contributing to common disease. Moreover, rare 
variant associations have the ability to identify specific genes and variants, rather than 
large genomic regions. This suggests that in the era of whole genome sequencing, 
genome-wide gene-based rare variant associations may be more powerful in identifying 
novel susceptibility loci.   
 In conclusion, we find an association between missense variants in CHRNB3 and 
CHRNA3 and alcohol and cocaine dependence symptom counts. Variants in CHRNB3 are 
associated with increased risk for cocaine dependence and alcohol dependence, while 
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variants in CHRNA3 are associated with decreased risk for cocaine dependence.  Both 
CHRNB3 and CHRNA3 are associated with cocaine dependence independently of 
smoking quantity as measured by CPD, a fact that is not surprising given the role of 
CHRN genes in the physiological response to multiple substances and the comorbidity of 
nicotine with both alcohol and cocaine use in human populations. We hypothesize that 
these variants act either by altering generalized reward pathways, by impacting 
impulsivity and related personality characteristics or by altering the effect of alcohol or 
cocaine on nicotinic receptors directly. Further sequencing of individuals for whom 
detailed dependence related information has been obtained is necessary to confirm and 
elaborate on these findings and functional studies will be necessary to elucidate the role 
of these genes on the physiological effects of cocaine.   
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Figure 3.1. Pooled Sequencing Scheme for COGA. DNA was quantified and pooled. The 
exons and flanking regions for the listed genes were amplified by PCR using PFU high-
fidelity polymerase, pooled and sequenced on an Illumina GAIIx.   
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Figure 3.2. Representative Error Model for COGA Pools. Each line is the average rate of 
change of each nucleotide changing to each of the other possible nucleotides for each of 
the possible positions within the Illumina sequencing read.  
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Figure 3.3. Schematics of the CHRN genes studied and the locations of missense variants 
identified in sequenced individuals from the COGA study. Each protein consists of a 
signal peptide, two extracellular domains, four transmembrane domains (TM1-4) and 
three intracellular domains. Conserved sites (phyloP44Vertebrate score > 2) are shown in 
grey, while all others are shown in black. 
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Figure 3.4. Distribution of DSM-IV Alcohol or Cocaine Dependence Symptom Count 
among carriers or non-carriers of A) any CHRNB3 variant or B) CHRNB3 H329Y among 
European American individuals in the COGA dataset 
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Figure 3.5. Distribution of CPD by number of DSM-IV cocaine dependence symptoms 
endorsed. Each red circle is proportional to the number of individuals with a given value 
of CPD calculated for each number of endorsed DSM-IV cocaine dependence symptoms 
endorsed. Proportions per number of symptoms endorsed was used to allow easier 
comparison of proportions across the range of symptom count despite differing numbers 
of individuals.   
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Figure 3.6. Distribution of DSM-IV cocaine symptom count by number of DSM-IV 
alcohol dependence symptoms endorsed. Each red circle is proportional to the number of 
individuals with a given number of cocaine symptoms endorsed calculated for each 
number of endorsed DSM-IV alcohol dependence symptoms endorsed. Proportions per 
number of symptoms endorsed was used to allow easier comparison of proportions across 
the range of symptom count despite differing numbers of individuals.   
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Figure 3.7. Distribution of CPD by number of DSM-IV alcohol dependence symptoms 
endorsed. Each red circle is proportional to the number of individuals with a given value 
of CPD calculated for each number of endorsed DSM-IV alcohol dependence symptoms 
endorsed. Proportions per number of symptoms endorsed was used to allow easier 
comparison of proportions across the range of symptom count despite differing numbers 
of individuals. 
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Chapter 4. Functional characterization of rare variants in CHRNB4 to improve the 
association between CHRNB4 and nicotine dependence 4 
 
ABSTRACT 
Smoking is the leading cause of preventable death worldwide. As such, effort has been 
devoted to determining what genetic variants contribute to smoking risk. Genome-wide 
association studies have identified variants in nicotinic acetylcholine receptor genes that 
contribute to nicotine dependence risk and follow up studies of these variants suggest that 
the same variants may play a role in multiple substance use disorders including alcohol 
and cocaine dependence. We previously undertook pooled sequencing of the coding 
regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and 
CHRNB3 genes and found that rare missense variants in CHRNB4 are associated with 
reduced risk of nicotine dependence. Recent in vivo studies have also implicated 
CHRNB4 in nicotine addiction: Mice over-expressing Chrnb4 have been shown to 
display a strong aversion to nicotine that can be reversed by virally mediated expression 
of Chrna5 D398N variant, a variant that reduces nicotinic receptor function, in the medial 
habenula 39. It has yet to be determined if rescue with wild-type Chrna5 is possible, 
however. Together, these results highlight the importance of understanding the function 
of variants in nicotinic acetylcholine receptors and CHRNB4 in particular. Our 
sequencing efforts, led to the identification of 18 rare (<5%) non-synonymous variants in 
CHRNB4 in a total of 2067 individuals from the Collaborative Study of the Genetics of 
Nicotine Dependence (COGEND) cohort. In order to investigate the effect of these 
variants, the normal or variant β4 subunit was co-expressed with normal α3 subunit in 
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human embryonic kidney 293 cells. Whole-cell voltage-clamp was used to obtain 
acetylcholine and nicotine concentration–response curves for each subunit combination. 
qRT-PCR, western blots and cell-surface ELISAs were performed to assess differences in 
mRNA production, overall CHRNB4 protein expression and cell-surface specific protein 
expression levels, respectively. Analysis of these data revealed several variants that 
affected nicotine EC50, acetylcholine EC50, maximal response to nicotine, maximal 
response to acetylcholine or nicotine efficacy. Nearly all variants tested lowered cell-
surface expression. These results highlight the need for detailed functional analysis of 
variants using multiple modalities and the advantages to integrating such data into human 
genetics.  
 
INTRODUCTION 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels 
formed from numerous combinations of receptor subunits, each encoded by a separate 
gene in the human genome. Neuronal nAChR α subunits are encoded by six genes 
(CHRNA2-A7, CHRNA9 and CHRNA10) and the β subunits by three genes (CHRNB2-
B4). A minimum of two α and two β subunits are required to form functional heteromeric 
receptors. This is because acetylcholine (ACh) binding occurs at the interface between α 
and β subunits. The only subunit capable of forming homomeric receptors is CHRNA7. 
Certain combinations of receptor subunits are more common in the human central 
nervous system (CNS). There exists profound regional specificity with regard to subtype 
expression in the mammalian CNS. The expression of the α3β4* subtype (the asterisk 
denotes any one of multiple accessory subunits), for instance, is limited for the most part 
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to autonomic and sensory ganglia, medial habenula, fasciculus retroflexus and the 
interpeduncular nucleus (IPN), while α4β2* receptors can be found almost ubiquitously 
throughout the brain 141-143.  
Recently, work has been done that suggests that the α3β4* subtype of nicotinic 
receptors may largely contribute to nicotine related behaviors by activating the habenulo-
interpeduncular pathway. The activity of the habenulo-interpeduncular pathway was 
recently shown to be increased during nicotine withdrawal and is involved in nicotine 
self-administration. Inhibiting α3β4* nicotinic receptors in the habenula reduces nicotine 
self-administration while blocking α3β4* nicotinic receptors in the IPN increases nicotine 
self-administration 144. Knocking out CHRNA5 results leads to dramatic increases in 
nicotine intake, even at high concentrations, and is reversible upon lentiviral expression 
of CHRNA5 in the medial habenula77. Further, mice over-expressing Chrnb4 were shown 
to display a strong aversion to nicotine, which was reversed upon virus-mediated 
expression of the a5 D398N variant in the medial habenula 39. This work suggests that 
aversion of nicotine in mouse is regulated by the balanced activity of β4 and α5 nicotinic 
receptor subunits in the medial habenula. Additionally, a recent association study of 
smoking cessation has shown that variants in CHRNB4 may decrease craving and 
withdrawal symptoms 91. These findings suggest that multiple nicotinic receptor subunit 
genes likely play a role in the development and maintenance of nicotine dependence and 
that variants in these genes may have different and in some cases opposing functional 
effects in humans and mice. 
Several variants in the CHRNB4 gene have been shown to affect receptor function 
using one of these in vitro assays 88. The CHRNB4 variants T91I, R136W, S140G, and 
	   84	  
M467V were each expressed heterologously in Xenopus oocytes and studied using the 
two-electrode voltage clamp. These experiments revealed that the R136W and M467V 
forms of the receptor had higher sensitivity to acetylcholine and lower EC50 than the 
wild-type. The T91I variant was shown to have lower sensitivity to acetylcholine and a 
larger EC50. Each of the T91I, R136W and M467V variants also showed greater 
desensitization after long-term exposure to low-dose acetylcholine. These results suggest 
that variants in nicotinic receptor genes alter receptor function in several ways, but also 
that more work needs to be done to fully understand the contribution of variation in the 
coding regions of CHRNB4 and other nicotinic receptor genes.  
Recently, multiple variants in or near nicotinic acetylcholine receptor genes have 
been found to be associated with nicotine related behavior in humans. A non-
synonymous change (rs16969968/D398N) in CHRNA5 is the most strongly associated 
SNP in several genome-wide association (GWA) studies of nicotine dependence. This 
variant was also shown to affect risk for cocaine dependence, although the risk allele for 
nicotine dependence decreases risk for cocaine dependence 61,62. Additionally, variants 
near CHRNA5 previously shown to alter CHRNA5 mRNA expression in vivo, alter risk 
for both nicotine and alcohol dependence 41,45. A group of common SNPs near the 
CHRNB3-CHRNA6 gene cluster were also shown to affect cigarette consumption in a 
recent GWAS 43. Sequencing of the neuronal nicotinic receptor genes in large cohorts of 
nicotine dependent cases and controls has also found associations between variants in two 
nicotinic receptor genes, CHRNA4 and CHRNB4, though we do not replicate the previous 
findings in CHRNA4. 52,138. In order to investigate the functional consequences of the 
variants associated with nicotine dependence from our study138, we constructed vectors 
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harboring variant CHRNB4 alleles, expressed the proteins in Hek293 cells and examined 
receptor function using several assays. These results were then incorporated into genetic 
association analyses. The goal of this chapter is to characterize the functional impact of 
rare variants in the CHRNB4 and CHRNA3 genes observed from sequencing a cohort of 
nicotine dependent individuals and non-dependent smoking controls in order to 
investigate the hypothesis that modeling the specific functional effects of variants in these 
genes, and genes more generally, could be used to improve association analyses of such 
variants with disease phenotypes. 
 
METHODS 
Generation and expression of constructs 
 Full-length coding sequences for the human nicotinic α3 (NP_000734.2) and β4 
(NP_000741.1) subunits were kindly provided by Dr. J. Lindstrom (University of 
Pennsylvania, Philadelphia, PA). Subunits were sub-cloned into the pcDNA3 vector 
(Invitrogen, San Diego, CA). Mutations were introduced using the QuikChange kit 
(Stratagene, San Diego, CA). The FLAG epitope [DYKDDDDK145] was introduced into 
α4 between the 6 and 7 positions of the mature polypeptide using QuikChange. For each 
construct the entire subunit coding region was sequenced to verify that only the desired 
mutation had been introduced.  
 
Cell culture and transfection. 
 HEK 293 cells (American Tissue Culture Collection, Gaithersburg, MD) were 
maintained in a mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 (1:1, 
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also containing L-glutamine and 15 mM HEPES), with 10% fetal bovine serum (Hyclone, 
Logan, UT), penicillin (100 units/ml) and streptomycin (100 ug/ml) in a humidified 
atmosphere containing 5% CO2 at 37°C. Cells were re-plated in the same medium the 
day before transfection. 
 For physiological and surface ELISA studies, subunits were transfected at a 1:1 
mass ratio using Effectene (QIAGEN, Valencia, CA) according to the manufacturer’s 
instructions. Briefly, 3 µg of cDNA per well of a 24-well dish was mixed with the 
Enhancer and the Effectene Transfection Reagent. The cells were incubated with the mix 
for 6 to 18 h. Electrophysiological experiments commenced the following day, while 
ELISAs were performed on the third day after transfections. 
 
Cell-Surface ELISAs 
 Surface ELISA assays were performed basically as described 146,147. Cells were 
plated in 24 well tissue culture plates at about 100,000 cells/well. The next day cells were 
transfected as described. In each experiment, a negative control (empty pcDNA3) and a 
positive control (wild-type subunits) were performed. Five wells were transfected with 
each subunit combination in each experiment; 3 were used for ELISA and 2 for a protein 
assay. For the ELISA assay, cells were rinsed in phosphate-buffered saline (PBS; 137 
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.4 mM KH2PO4, pH 7.3) then blocked 
for 30 min at room temperature with 4% powdered milk in PBS (milk-PBS). To detect α3 
mAb 35 was used as primary antibody (Sigma-Aldrich, St. Louis MO; diluted 1:400 in 
milk-PBS) for 1 h at room temperature. Cells were then washed twice with milk-PBS and 
incubated with anti-rat IgG peroxidase-conjugated goat antibodies (Sigma, A9037; 1:100 
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dilution in milk/PBS) for 1 h and washed with PBS four times. To detect FLAG-tagged 
α4, cells were incubated with M2 antibody (Sigma-Aldrich, 2 µg/ml in milk-PBS) as 
described and then incubated with anti-mouse IgG peroxidase-conjugated goat antibodies 
(Sigma, A9037; 1:100 dilution in milk/PBS) for 1 h. After incubation with secondary 
antibody, cells were washed 4 times with PBS, and then assayed using the 1-Step Ultra 
TMB-ELISA kit (Pierce, Rockford, IL). Absorbance was read at 405 nm using a 
microplate reader (iMark, Biorad, Hercules CA). Total cell protein was assayed from 
wells that had been maintained in milk-PBS, then washed twice with PBS before assay 
by a bicinchoninic acid method (Pierce). For each experiment, the ELISA signal was 
obtained from triplicate wells and the cell protein from duplicate wells.  
 The surface ELISA data were analyzed as follows. The machine background was 
subtracted from each OD reading, then the OD readings were divided by the protein for 
that subunit combination. The normalized value for the negative control (pcDNA3) for 
that experiment was then subtracted from all values. Finally, to control for variation in 
expression between experiments, the subtracted expression levels were normalized to the 
positive control (wild-type) value for that experiment. The final value gives an estimate 
of the relative expression where a value of 1 indicates identical expression to wild-type 
subunits.  
 
Western Blots  
To measure CHRNB4 protein levels in HEK293 cell lines transiently transfected 
with pcDNA3-empty, pcDNA3-CHRNA3-Wild-Type and pcDNA3-CHRNB4-Wild-Type, 
or pcDNA3-CHRNA3-WT and pcDNA3-CHRNB4-Mutant plasmids, we performed 
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western blots on cell lysates using a poly-clonal CHRNB4 antibody generously provided 
by Dr. Cecelia Gotti. Cells were seeded into 6-well lysine-coated plates and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 1% L-glutamine, and penicillin/streptomycin. Cells were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol incubated in a 
humidified atmosphere containing 5% CO2 at 37°C. After two days of growth, each well 
of the 6-well plate was used to create a cell-lysate. Cells were lysed with 150ul of lysis 
buffer (50 mM Tris, 150 mM NaCl, 2 mM EDTA, 0.25% NP40, 1% TritonX). Total 
protein concentration was then measured by BCA assay for each cell lysate. 20ug of 
protein from each lysate was then incubated at 95°C for 5 minutes in 1x lamellae buffer 
(0.25 M Tris, 8% SDS, 40% glycerol, 0.01% bromophenol blue dye and 20% β-
mercaptoethanol). Denatured samples were then loaded onto a 4-20% Criterion gel in 
TG-SDS buffer (0.01% SDS, 25 mM Glycine, 2.5 mM Tris) and run at 125V ffor 90 
minutes. Protein in the gel was then transferred to a nitrocellulose membrane in TG-SDS 
buffer containing 20% methanol overnight at 4°C. Blots were then incubated in TG-SDS 
containing 4% milk for 25 minutes at room temperature, incubated at room temperature 
with a primary CHRNB4 poly-clonal antibody for 90 minutes, rinsed 3x with PBS 
containing 1% Triton-X for 5 minutes, incubated with a horseradish peroxidase 
conjugated secondary antibody, washed 3x with PBS containing 1% Triton-X for 5 
minutes and finally incubated with the horseradish peroxidase substrate 3, 3, 5, 5, 0-
tetramethylbenzidine before images were taken allowing for 5 minutes of exposure using 
a Syngene western blot imager.  
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mRNA Expression 
 To measure CHRNB4 mRNA production in HEK 293 cells transiently 
transfected with pcDNA3-empty, pcDNA3-CHRNA3-Wild-Type and pcDNA3-
CHRNB4-Wild-Type, or pcDNA3-CHRNA3-WT and pcDNA3-CHRNB4-Mutant 
plasmids, RNA was extracted from cell lysates with an RNeasy kit (Qiagen). Extracted 
RNA (10 ug) was then converted to cDNA using the High Capacity cDNA Reverse 
Transcriptase kit (ABI). CHRNB4 mRNA expression was then measured using sybrgreen 
(Invitrogen) using one primer spanning exons 3 and 4 and another primer spanning exons 
4 and 5 to ensure only cDNA was amplified.  
 
Whole-cell patch clamp 
 Cells were plated in 35 mm tissue culture dishes, and maintained and transfected 
as described. For recordings, cells were rinsed with recording bath solution (140 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, and 10 mM HEPES, pH 
7.4) and cells expressing high levels of surface receptors were identified by a bead-
binding technique 86.We used mAb35 (Sigma-Aldrich) to identify α3 and mAb199 for α4 
(Sigma-Aldrich). Antibody was adsorbed to immunobeads with a covalently attached 
secondary antibody (Invitrogen). The cells were incubated with a suspension of beads for 
5 to 10 min with gentle shaking, and cells expressing surface receptors were identified 
from the presence of beads bound to the cell. This greatly enhanced our ability to identify 
cells expressing measurable numbers of receptors. 
 Macroscopic currents were recorded using whole-cell voltage clamps described 
before 86. A diagram of the whole-cell voltage clamp technique can been seen in figure 
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4.1. The pipette (intracellular) solution contained 140 mM CsCl, 4 mM NaCl, 4 mM 
MgCl2, 0.5 mM CaCl2, 5 mM EGTA, and 10 mM HEPES, pH 7.4. The drugs were 
applied through the bath using an SF-77B fast perfusion stepper system (Warner 
Instruments, Hamden, CT). Currents were recorded using an Axopatch 200 amplifier 
(Molecular Devices, Union City, CA). The cells were clamped at -60 mV. All 
experiments were carried out at room temperature (19–22°C). The current traces were 
low-pass filtered at 2 kHz and digitized at 10 kHz. The analysis of whole-cell currents 
was carried out using the pClamp 9.0 software package (Molecular Devices). 
 The basic parameter measured was the peak response to a given concentration of 
acetylcholine (ACh) or nicotine. Four second pulses of agonist were applied at intervals 
of 30 seconds with continuous application of bath solution between pulses to allow 
recovery from desensitization. Concentration-response relationships were constructed by 
applying pulses of differing agonist concentration. The data from a cell were analyzed by 
fitting with the Hill equation: Y(X) = a(1/(1+{X/k}^n)) where Y(X) is the response to a 
concentration X, and the parameters a (maximal response), k (EC50 or concentration 
giving half-maximal response) and n (Hill coefficient) were determined by non-linear 
regression using SigmaPlot (Systat Software, Chicago IL). To combine data, the 
relationships were scaled by the fit maximum. In some cases, it was clear that high 
concentrations of agonist produced a reduced response, likely due to open-channel block 
by the agonist 148-150. Accordingly, responses to high concentrations that produced a 
lower response than responses to lower concentrations were not included in the fit. 
 Concentration-response data for ACh and nicotine were obtained on different 
cells, to minimize the duration of whole-cell recording. Previous work has demonstrated 
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that there can be changes in the peak response and/or the desensitization properties of 
neuronal nicotinic receptors over the time of whole-cell recording 150,151. Accordingly, 
each cell was tested with a high concentration of ACh (usually 1 mM), and this value was 
used to normalize the nicotine concentration-response relationship to the overall averaged 
ACh concentration-response relationship for that particular subunit combination. 
Similarly, some cells were tested with single applications of a high concentration of ACh 
and a high concentration of nicotine to obtain estimates for relative maximal responses. 
In this case, the relative maximal response to nicotine was normalized to both the mean 
concentration-response data for nicotine and for ACh for that subunit combination. 
 The fact that cells were not randomly selected means that the average response to 
a maximal concentration of ACh does not give a direct estimate of the number of 
activatable receptors on an average cell and so is not comparable to the surface ELISA 
signal. There was a general correlation between the average maximal response and the 
ELISA signal. 
 
Drugs, data presentation and statistics. 
 Unless otherwise noted all chemicals used were obtained from Sigma-Aldrich.  
Data are presented as mean ± SE (number of observations). For ELISA studies results 
from each experiment constituted one observation; data were obtained in triplicate in 
each experiment. For physiological results each cell constituted an observation (i.e. EC50, 
or maximal response).  
 Parameters from fitting the Hill equation were excluded from analysis if the 
standard error of any fit parameter for that cell (as estimated by the fitting program) was 
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60% or more than the best fitting value. Data from ELISA experiments were excluded if 
the expression for the positive control was less than 3-times pcDNA3, indicating a failed 
transfection. 
 Basic statistical computations were made with Excel (Microsoft, Redmond WA). 
ANOVA was performed using Stata (StataCorp, College Station TX). Figures were 
prepared with SigmaPlot.  
 The homology model was made by threading the α3 and β4 subunits onto the α 
and δ subunits respectively of the Torpedo marmorata cryoelectron microscopic structure 
(152; PDB 2BG9) using the SWISS-MODEL web tool (http://swissmodel.expasy.org/). 
Structures were visualized and displays generated using Chimera 1.6.2 
(http://www.cgl.ucsf.edu/chimera). 
 
Samples and Phenotype 
DNA samples were collected as part of the Collaborative Genetic Study of Nicotine 
Dependence (COGEND). All members of the COGEND sample underwent a semi-
structured interview, which assessed smoking behavior, other substance use and 
comorbid psychiatric conditions. The COGEND sample includes 710 African Americans 
(461 nicotine dependent (ND) cases and 249 smokers with no symptoms of dependence 
(controls)) and 2055 European Americans (1062 ND cases and 993 controls). As these 
individuals were ascertained to study nicotine dependence, Fagerström Test of Nicotine 
Dependence (FTND) scores (Range= 1-10) were required to be <1 for controls and >4 for 
cases. In all cases lifetime maximum FTND score was used. All members were required 
to have smoked at least 100 cigarettes in their lifetime. Because in our original analyses 
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the association between rare missense variants and CPD in African Americans was the 
strongest, we used this as our primary sample and phenotype when assessing whether 
functional characterization of alleles could improve observed associations. As linear 
regression was used and requires normally distributed variables, we log-transformed CPD 
such that it was normally distributed. A total of 352 African Americans (176 ND cases 
and 176 smoking controls) and 400 European Americans (200 ND cases and 200 
smoking controls) were sequenced in the original study. Follow up genotyping of SNPs 
identified and validated in the sequenced individuals was done in the remaining portion 
of the COGEND sample (310 African Americans and 1662 European Americans).  
 
Association Analysis 
Association analyses were performed in R using linear regression incorporating age and 
sex as covariates. To analyze carrier status, individuals were coded as either 0 or 1 
depending on whether they carried 0 or ≥ 1 missense variants at any position in CHRNB4. 
Carrier status was tested in a linear regression against logCPD with age and sex as 
covariates. For all variant combinations of multiple CHRNB4 variants occurring in at 
least one individual, plasmids were created that harbored both variants. To analyze the 
function-weighted carrier status, individuals were coded as either 0 or 1 depending on 
whether they carried 0 or ≥ 1 missense variants at any position in CHRNB4 and then the 
person’s code was multiplied by the normalized value for each of the tested parameters 
(Acetylcholine EC50, Nicotine EC50, acetylcholine maximal response, nicotine maximal 
response and nicotine efficacy). These values were then used as the predictor in a linear 
regression using age and sex as covariates.  
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RESULTS 
Pharmacological Profiles of Variant containing α3β4 Receptors 
A total of 10 rare missense variants were identified in CHRNB4 as part of the 
previous sequencing projects. These variants can be found in many domains of the 
mature protein, but many occur within the first extracellular domain (Figure 4.40). To test 
the electrophysiological properties of β4 containing nicotinic receptors constructed to 
harbor these variant alleles, wild-type α3 and variant containing β4 receptor subunits 
were co-expressed in HEK 293 cells. Responses from cells were measured upon exposure 
to between 1 and 10,000 µM ACh and subsequently to 1 to 300 µM nicotine. 
Representative traces and resultant concentration response curves can been seen in figure 
4.41. Concentration response curves for nicotine for each variant can been seen in figures 
4.9-4.23. Concentration response curves for acetylcholine can be seen in figures 4.24-
4.39. Several variants show altered response to nicotine. Specifically, nicotine EC50 was 
altered for two variants (M456V and K57E) and nicotine efficacy was altered for one 
CHRNB4 variants (T91I) when combined with the α3 variant R37H, a variant that almost 
always accompanies T91I in individuals of both African and European descent. Values 
and statistical significance for all electrophysiological assays can be seen in Figure 4.41, 
4.42, 4.45 and tables 4.1, 4.2 and 4.3. No variants observed during sequencing 
significantly affected any electrophysiological parameters when expressed with α4 
subunits rather than α3.  
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Cell-Surface ELISAs 
In order to determine the extent to which mutations in CHRNB4 and CHRNA3 alter the 
steady-state level of nAChR protein expressed on the cell-surface, we performed ELISAs 
on cultured HEK 293 cells two days after transient transfection with constructs 
expressing wild-type CHRNA3 and either wild-type CHRNB4 or mutant CHRNB4. A 
diagram of the technique can been seen in figure 4.2. Cell-surface expression was 
decreased for nearly all variants tested (Figure 4.44, Table 4.3 and Table 4.4.). The 
S140G variant is predicted to abolish glycosylation at amino-acid position 138. The S is 
third amino acid in the consensus glycosylation signal NXS, where X can be any amino 
acid. We hypothesized that the absence of glycosylation at this site results in low cell-
surface protein expression of this variant. First, to test this hypothesis, we created a 
CHRNB4 expressing plasmid containing an alanine (A) at position 138, rather than the 
asparagine (N) required for glycosylation at this site as well as a plasmid containing a 
threonine (T) at position 140, predicted to retain glycosylation but change the amino acid 
at position 140.  Cell-surface ELISAs demonstrated cell-surface protein levels of the 
N138A variant to be low and similar in level to the S140G variant while the S140T 
variant showed cell-surface protein levels more closely resembling wild-type CHRNB4, 
albeit reduced (Figure 4.44, Table 4.3 and Table 4.4.). These data suggest that at least for 
the S140G variant, it is ablation of glycosylation at this position that explains the 
reduction in cell-surface protein expression of S140G variant receptors. We also observe 
a significant correlation between relative cell-surface ELISA results when variant 
containing subunits are expressed with α3 or α4 subunits (Figure 4.46) and a significant 
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correlation between relative maximal response to acetylcholine and relative cell-surface 
ELISA levels when expressed with α3 but not α4 (Figure 4.47).  
Western Blots 
In order to determine if overall CHRNB4 protein, both intra-cellular and cell-surface, was 
altered by the introduction of mutation, we performed western blots on total cell lysates 
from HEK 293 cells transiently transfected with wild-type CHRNA3 containing plasmids 
and either wild-type or mutant CHRNB4 containing plasmids. Analysis of the band 
intensity for each mutant protein provided no evidence of altered total CHRNB4 
expression for any of the variant plasmids (Figure 4.3, 4.4, 4.5 and Figure 4.8). Of note, 
each of the variants predicted to alter glycosylation at amino-acid position 138 (S140G, 
N138A and S138A/S140G) show shifts in their full-length protein band in the expected 
direction assuming a disruption of glycosylation (Figure 4.3). Further, these differences 
in apparent molecular mass were normalized upon incubation with PNGase to remove all 
glycosylation (Figure 4.6 and Figure 4.7).   
 
Association Analyses  
To determine if incorporation of results from our functional analyses of all 
variants known to exist in our study population could be used to improve power to detect 
an association between nicotine related behaviors and variants in CHRNB4, we created a 
genotype model weighted based on the predicted maximal nicotine response of each of 
the variants. We used each parameter estimated from a variant’s concentration response 
curves for nicotine and acetylcholine as well as cell-surface protein level to create 
quantitative measures of receptor function that we could assign to each individual based 
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on the alleles they harbor. We first performed an analysis simply using carrier status at 
any non-synonymous site in CHRNB4 as the predictor variable in a linear regression with 
log transformed lifetime maximum number of cigarettes smoked per day (logCPD) as the 
response variable and including age and sex as covariates. Using all missense variants, 
there is no significant association between carrying at least one missense variant in 
CHRNB4 and logCPD (β = -0.038, p= 0.585, r2 = 0.0009) (Figure 4.48). We then took the 
subset of missense variants that occurred at genomic positions with at least suggestive 
levels of cross-species conservation (vertebrate PhyloP scores > 2). This reduced the 
number of variants from ten to six. We observed a modest, but significant association 
between carrying at least one missense variant at a conserved site in CHRNB4 and 
number of cigarettes smoked/day (β = -0.24, p-value = 0.008, r2 = 0.009) (Figure 4.49). 
We then weighted each variant genotype by the value for each of the estimated 
electrophysiological parameters (nicotine EC50, acetylcholine EC50, maximal response to 
nicotine, maximal response to acetylcholine, nicotine efficacy) or relative cell-surface 
expression level. The results of this weighting procedure can be seen in Figures 4.50- 
4.55. Weighting in this way by acetylcholine EC50 explained substantially more 
phenotypic variance and produced an association that would be considered genome-wide 
significant for gene-based associations assuming a multiple test correction for 20,000 
genes (β = -0.006, p-value = 6x10-6, r2 = 0.029). These results suggest that substantial 
power can be gained by incorporating knowledge of the functional effects of variants into 
genetic association analyses.  
 
DISCUSSION 
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The goal of this chapter was to characterize the functional impact of rare variants 
in the CHRNB4 and CHRNA3 genes observed from sequencing a cohort of nicotine 
dependent individuals and non-dependent smoking controls in order to investigate the 
hypothesis that modeling the specific functional effects of variants in these genes, and 
genes more generally, could be used to improve association analyses of such variants 
with disease phenotypes. To do so we performed electrophysiological experiments, cell-
surface ELISAs, western blot assays and qRT-PCR to thoroughly describe the effects of 
variants in these genes on receptor expression and function. Some variants had little 
effect on receptor function. However, most variants had some measurable effect on cell-
surface protein expression compared to wild-type. As several variants have strong effects 
on cell-surface protein expression despite having no measurable effect on smoking 
behavior, it seems reasonable that alterations to protein function are better indicators of 
whether or not a variant will affect behavior. Additionally, as the intracellular protein 
level is generally much higher than at the cell-surface, individuals heterozygous for 
mutations that cause lower cell-surface expression when expressed alone may be 
compensated for by their non-variant allele. While many variants perturbed the cell-
surface protein levels of the receptors they were incorporated into, none substantially 
altered total CHRNB4 protein expression. Additionally, only a small number of the 
characterized variants significantly affected aspects of nicotine or acetylcholine response. 
The significant relationship between small perturbations of protein function when taken 
together and a complex human behavior like nicotine dependence suggests that precise 
measurements of allele function are critical. These findings also suggest that it is 
important to investigate multiple avenues of protein function alteration to fully 
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characterize the impact of variants. Though mildly correlated, the electrophysiological 
parameters used in this study likely have distinct effects on cognition and the role of 
exogenous chemicals like nicotine in brain chemistry. 
Overall, the results from our electrophysiological assays are consistent with 
findings reported previously by others 88. These experiments revealed that the R136W 
and M467V variants had higher sensitivity to acetylcholine and lower EC50 than the wild-
type and that the T91I variant had lower sensitivity to acetylcholine and a larger EC50. 
We confirm these results, despite having performed the experiments in transiently 
transfected HEK 293 cells and CHRNB4 variant subunits were expressed with CHRNA3 
rather than CHRNA4. Though not significant, the Liang et al. study also found the S140G 
variant to increase acetylcholine EC50, consistent again with our findings.  
We hypothesized that functional characterization of variants could improve power 
to detect associations between assayed rare variants in a gene-based burden-like test. In 
order to test this, we performed a regression based rare variant burden test in which 
variants were weighted in proportion to their effect on each of the following 
concentration response curve parameters: acetylcholine EC50, nicotine EC50, 
acetylcholine maximal response, nicotine maximal response, nicotine efficacy and cell-
surface expression. We find that acetylcholine EC50 was the best predictor of behavior as 
measured by log(CPD). No other parameter improved our ability to observe an 
association at this locus. Overall, our results suggest that this approach of incorporating 
functional information can improve power to detect associations if relevant parameters 
are measured and that methods of assaying the functional impact of variants across the 
genome will likely greatly improve gene discovery in the era of whole-exome and whole-
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genome sequencing. The reduction in power resulting from large proportions of variants 
with little or no impact on protein function or mixtures of protective and risk variants 
being included in gene-based burden tests is substantial and will have to be addressed if 
we hope to understand the full scope of variation impacting common complex diseases 
and traits.  
In conclusion, we find that the majority of missense variants in CHRNB4 and 
CHRNA3 alter receptor function or receptor cell-surface expression. Further, these 
findings may be used to inform genetic association analyses to improve power to detect 
signals often obscured by more common neutral or near neutral alleles. These findings 
highlight the need for the integration of functional studies into the findings of human 
genetics.  
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Figure 4.1. Mechanics of whole-cell voltage clamp. First a glass pipette with slight 
negative pressure is applied to the outside of a cell. A brief burst of suction is the applied 
to break the cell membrane, allowing the inside of the pipette to be continuous with in the 
inside of the cell. The degree to which the cell is depolarized upon treatment with an 
agonist or antagonist is then monitored. Figure is taken from: http://www.leica-
microsystems.com/science-lab/the-patch-clamp-technique/.  
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Figure 4.2. Schematic of Cell-Surface ELISA assay Mechanics. Cells transiently 
transfected with plasmids expressing wild-type CHRNA3 in addition to either wild-type 
CHRNB4 or variant containing CHRNB4 are incubated with primary antibody against the 
extracellular domain of CHRNA3 derived from rat (purple). The cultures are then 
incubated with a horseradish peroxidase conjugated anti-rat secondary antibody (blue) 
and then allowed to induce color change in tetramethylbenzidine (white circles and 
orange cirles). Figure adapted from .   
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Figure 4.3. Western Blot of S140G and related variants. N138A, S140G and the doubly 
mutated plasmid containing both N138A and S140G, all predicted to affect glycosylation 
at residue 138, run more quickly through a polyacrylamide gel than do either S140T or 
wild-type proteins, both predicted to permit glycosylation at residue 138.  
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Figure 4.4. Total CHRNB4 protein level for variant residues 57-136. Images are 
representative of 6 replicate transfections averaged for statistical analyses. Protein levels 
were normalized to beta-tubulin levels (bottom).   
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Figure 4.5. Total CHRNB4 protein level for variant residues 296-467. Images are 
representative of 6 replicate transfections averaged for statistical analyses. Protein levels 
were normalized to beta-tubulin levels (bottom).   
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Figure 4.6. Total and PNGase digested CHRNB4 protein levels and size shifts for variant 
residues related to glycosylation. Incubation with PNGase F normalizes the distance run 
on a polyacrylamide gel for variants predicted to affect glycosylation and those that are 
not.  
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Figure 4.7. Total and PNGase digested CHRNB4 protein levels and size shifts for variant 
residues related to glycosylation. Incubation with PNGase F normalizes the distance run 
on a polyacrylamide gel for variants predicted to affect glycosylation and those that are 
not.  
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Figure 4.8. Western blot quantification. Replicates across multiple days of transfection 
were averaged  and normalized to wild-type CHRNB4 protein level.    
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Figure 4.9. Nicotine concentration response curve for wild-type and R37H containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.10. Nicotine concentration response curve for wild-type and K57E containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.11. Nicotine concentration response curve for wild-type and T91I containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.12. Nicotine concentration response curve for wild-type and R136W containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.13. Nicotine concentration response curve for wild-type and R136Q containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.14. Nicotine concentration response curve for wild-type and S140G containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.  
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Figure 4.15. Nicotine concentration response curve for wild-type and R349C containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.16. Nicotine concentration response curve for wild-type and T375I containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.  
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Figure 4.17. Nicotine concentration response curve for wild-type and M456V containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.18. Nicotine concentration response curve for wild-type and M467V containing 
nicotinic receptors. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.19 Nicotine concentration response curve for wild-type nicotinic receptors and 
nicotinic receptors composed of R37H CHRNA3 and T91I CHRNB4. Variant (red curve) 
response parameters were then estimated and compared to wild-type (black curve) 
parameters.   
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Figure 4.20. Nicotine concentration response curve for wild-type nicotinic receptors and 
nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V 
CHRNB4 and R136W CHRNB4. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters.   
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Figure 4.21. Nicotine concentration response curve for wild-type nicotinic receptors and 
nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V 
CHRNB4 and S140G CHRNB4. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.22. Nicotine concentration response curve for wild-type nicotinic receptors and 
nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the M467V 
and R136W variants. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.23. Nicotine concentration response curve for wild-type nicotinic receptors and 
nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the M467V 
and S140G variants. Variant (red curve) response parameters were then estimated and 
compared to wild-type (black curve) parameters.   
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Figure 4.24. Acetylcholine concentration response curve for wild-type and CHRNA3 
R37H containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters.   
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Figure 4.25. Acetylcholine concentration response curve for wild-type and CHRNB4 
K57E containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.26. Acetylcholine concentration response curve for wild-type and CHRNB4 
K57E containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.27. Acetylcholine concentration response curve for wild-type and CHRNB4 
R136W containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.28. Acetylcholine concentration response curve for wild-type and CHRNB4 
R136Q containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.29. Acetylcholine concentration response curve for wild-type and CHRNB4 
S140G containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.30. Acetylcholine concentration response curve for wild-type and CHRNB4 
G296S containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.31. Acetylcholine concentration response curve for wild-type and CHRNB4 
R349C containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.32. Acetylcholine concentration response curve for wild-type and CHRNB4 
T375I containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.33. Acetylcholine concentration response curve for wild-type and CHRNB4 
M456V containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
 
 
 
  
!"!!#
!"$!#
%"!!#
%# %!# %!!# %!!!# %!!!!#
&'
()
*+
'#
&'
,-
./
,'
#
012.*/'#3./2'/45)*./#6789#
:1(;<4=-'#
8>$?@#
Acetylcholine	  Concentration	  (uM)	  
	   134	  
 
 
 
 
 
 
 
 
 
 
Figure 4.34. Acetylcholine concentration response curve for wild-type and CHRNB4 
M467V containing nicotinic receptors. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.35. Acetylcholine concentration response curve for wild-type nicotinic receptors 
and nicotinic receptors composed of R37H CHRNA3 and T91I CHRNB4. Variant (red 
curve) response parameters were then estimated and compared to wild-type (black curve) 
parameters. 
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Figure 4.36. Acetylcholine concentration response curve for wild-type nicotinic receptors 
and nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V 
CHRNB4 and R136W CHRNB4. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.37. Acetylcholine concentration response curve for wild-type nicotinic receptors 
and nicotinic receptors composed of wild-type CHRNA3 and a 1:1 mixture of M467V 
CHRNB4 and S140G CHRNB4. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.38. Acetylcholine concentration response curve for wild-type nicotinic receptors 
and nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the 
M467V and R136W variants. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.39. Acetylcholine concentration response curve for wild-type nicotinic receptors 
and nicotinic receptors composed of wild-type CHRNA3 and CHRNB4 with both the 
M467V and S140G variants. Variant (red curve) response parameters were then 
estimated and compared to wild-type (black curve) parameters. 
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Figure 4.40. Location of variants in a homology model of the α3β4 receptor. A homology 
model of the receptor was made by threading the α3 and β4 subunits onto the α and δ 
subunits respectively of the Torpedo marmorata cryoelectron microscopic structure 152; 
PDB 2BG9) using the SWISS-MODEL web tool (http://swissmodel.expasy.org/). 
Structures were visualized and displays generated using Chimera 1.6.2 
(http://www.cgl.ucsf.edu/chimera). The subunits are shown as chain trace (α3 red, β4 
cyan) with the ACh-binding loops highlighted (α3 yellow, β4 blue). Variants are shown 
as stick and ball: α3(R37) (red), β4(K57) - dark blue, β4(T91) - orange, β4(R136) - pink, 
β4(S140) - purple, β4(G296) - dark green, β4(R349) - in unstructured region (not shown), 
β4(T375) - in unstructured region, β4(M456) - dark green, β4(M467) - light green. None 
of the variants are in the transmitter-binding site, nor are they at regions likely to be 
points of interaction between subunits. β4(G296) is located in the 3rd and β4(M467) in 
the 4th membrane spanning region, but none are located in the channel/gate regions of 
the 2nd membrane spanning region. 
	   141	  
 
Figure 4.41. Responses to acetylcholine and nicotine from cells expressing wild-type α3 
and β4 subunits. Panel A shows data from one cell for responses to ACh, and panel B 
responses to nicotine (from a different cell). The traces in red are response to the highest 
concentration; note that the responses decline more rapidly and show a "tail" of increased 
response when the agonist is removed. This is characteristic of channel block by agonist. 
On the right, the normalized concentration-response curves are shown; red triangles show 
data from the traces on the left, while blue circles show the mean (± SE) data for 20 cells 
(ACh) or 9 cells (nicotine). The lines show predictions of the Hill equation:  
 response = Amp x ([agonist]/EC50)^nHill / (1 + ([agonist]/EC50)^nHill ) 
where Amp is the maximal response, EC50 is the concentration producing a half-maximal 
effect, and nHill is the Hill coefficient. For individual cell data the values used were the 
best-fitting values for that cell while for the mean data the values were the mean values 
for all fits to data obtained with that agonist. Data for nicotine were normalized to the 
maximal response to ACh. 
A
B
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Figure 4.42. Parameters normalized to that for wild-type, for receptors containing 
combinations of α3(R37H) with β4 variants. The panels show the surface expression, 
then the relative efficacy for nicotine, the EC50 for nicotine and the EC50 for ACh. Each 
pair of bars shows data for α3 or α3(R37H) expressed with the specified β4 subunit. The 
symbols on the right show significance of the difference to α3β4, first for α3 with the β4 
subunit then for α3(R37H) (ns: >0.05, * <0.05; ** < 0.01; *** < 0.001). (Data are mean+ 
SE). 
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Figure 4.43. Parameters normalized to that for wild-type, for receptors containing 
combinations of β4(M467V) with other variants, all expressed with α3. Variants were 
combined on the same subunit (e.g. β4(M467V + S140G), or expressed as a 1:1 mixture 
of subunits (e.g. β4(M467V)&β4(S140G)). The figure is in the same format as previous 
figures. 
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Figure 4.44. Surface expression for β4 variants expressed with the α3 or the α4 subunit. 
Each pair of bars shows data for the specified β4 subunit expressed with either the α3 or 
α4 subunit. The symbols on the right show significance of the difference to expression of 
wild-type β4, first for α3 then for α4 (ns: >0.05, * <0.05; ** < 0.01; *** < 0.001).  (Data 
are mean+ SE). 
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Figure 4.45. Physiological parameters normalized for β4 variants normalized to values 
for wild-type β4. Each pair of bars shows data for the indicated variant expressed with 
either α3 or α4 subunits. The symbols on the right show significance of the difference to 
parameters for wild-type β4, first for α3 then for α4 (ND not determined; ns: >0.05; * 
<0.05; ** < 0.01; *** < 0.001).  (Data are mean+ SE). 
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Figure 4.46. Scatter plot of expression of β4 variants with the α4 subunit against 
expression with the α3 subunit. Each point shows the mean ± SE, while the solid point 
shows the value for wild-type β4. The dashed line shows the line of equality, and the 
solid line shows the regression relationship (slope = 1.36, different from a slope of 0 with 
P = 0.01). The relationship is consistent with the idea that the variants do not have a 
selective effect on expression with a specific α subunit, but rather affect maturation, 
general ability to be assembled or trafficking to the surface. 
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Figure 4.47. Scatter plots of the average maximal response to ACh for expression of β4 
variants against the surface expression. The left panel shows data for variants expressed 
with the α3 subunit, the right panel for expression with the α4 subunit. Each point shows 
the mean ± SE, while the solid point shows the value for wild-type β4. In each panel the 
dashed lines show the line of equality, and the solid lines show the regression relationship. 
For expression with α3 the slope = 0.54 that differs from a slope of 0 with P = 0.01. For 
expression with α4 the slope = 0.17 that does not differ from a slope of 0 (P = 0.5). The 
maximal response was determined with cells selected for high surface expression while 
the surface ELISA measures the average surface expression per cell. Accordingly, it 
might be expected that variants with low expression would have a larger relative response 
compared to wild-type than surface ELISA.  
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Figure 4.48. Normalized cigarettes per day among carriers of CHRNB4 missense variants. 
Residuals of log transformed cigarettes per day (CPD) after correcting for age and sex 
were compared between individuals carrying at least one missense variant in CHRNB4 
and those not carrying any missense variants in CHRNB4 using linear regression in R.  
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Figure 4.49. Normalized cigarettes per day among carriers of CHRNB4 missense variants 
at conserved (vertebrate PhyloP score >2) sites.  Residuals of log transformed cigarettes 
per day (CPD) after correcting for age and sex were compared between individuals 
carrying at least one missense variant in CHRNB4 at a conserved site and those not 
carrying missense variants at conserved sites using linear regression in R.  
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Figure 4.50. Correlation between Acetylcholine EC50 and CPD. A) The distribution of 
log(CPD) after correcting for age and sex for each CHRNB4 variant’s estimated 
acetylcholine EC50. Red line is the estimated linear relationship. B) Box plots of 
log(CPD) after correcting for age and sex for each variant or group of variants (i.e. 
individuals with two variants) ordered by acetylcholine EC50 value.   
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Figure 4.51. Correlation between Nicotine EC50 and CPD. A) The distribution of 
log(CPD) after correcting for age and sex for each CHRNB4 variant’s estimated nicotine 
EC50. Red line is the estimated linear relationship. B) Box plots of log(CPD) after 
correcting for age and sex for each variant or group of variants (i.e. individuals with two 
variants) ordered by nicotine EC50 value.  
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Figure 4.52. Correlation between Nicotine efficacy and CPD. A) The distribution of 
log(CPD) after correcting for age and sex for each CHRNB4 variant’s estimated nicotine 
efficacy. Red line is the estimated linear relationship. B) Box plots of log(CPD) after 
correcting for age and sex for each variant or group of variants (i.e. individuals with two 
variants) ordered by nicotine efficacy value.  
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Figure 4.53. Correlation between Cell-Surface Expression of CHRNB4 variants when 
expressed with CHRNA3 and CPD. A) The distribution of log(CPD) after correcting for 
age and sex for each CHRNB4 variant’s estimated cell-surface expression . Red line is the 
estimated linear relationship. B) Box plots of log(CPD) after correcting for age and sex 
for each variant or group of variants (i.e. individuals with two variants) ordered by cell-
surface expression value.  
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Figure 4.54. Correlation between acetylcholine maximal response and CPD. A) The 
distribution of log(CPD) after correcting for age and sex for each CHRNB4 variant’s 
estimated acetylcholine maximal response. Red line is the estimated linear relationship. 
B) Box plots of log(CPD) after correcting for age and sex for each variant or group of 
variants (i.e. individuals with two variants) ordered by acetylcholine maximal response 
value.  
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Chapter 5. Conclusions and Future Directions 
 
State of substance dependence research prior to this work 
 Despite the efforts of many candidate gene studies and several large meta-
analyses consisting of >40,000 individuals, very few genes that contribute to the risk of 
nicotine dependence or cigarette consumption have been identified. Further, the genes 
identified have been excellent candidate genes. The two classes of genes that have been 
identified as contributors to nicotine dependence risk are nicotinic acetylcholine receptors, 
CHRNA5/B4/A3 on chromosome 15 and CHRNA6/B3 on chromosome 8, and CYP2A6, 
the major nicotine metabolizing enzyme, the only non-nicotinic receptor gene to be 
significantly associated with the number of cigarettes smoked per day (CPD) at the 
genome-wide level.  A few sequencing studies had investigated the role of rare variants 
in select nicotinic acetylcholine receptor genes prior to the commencement of this work 52. 
These studies were limited to cohorts of European Americans and only limited numbers 
of individuals were sequenced. The only survey of common variation and nicotine 
dependence, as opposed to CPD, was in a tandem candidate gene and genome-wide 
survey that examined 3718 SNPs in 348 candidate genes in conjunction with a pooled 
genome-wide association study of >2.4 million variants followed by individual 
genotyping of ~40,000 variants 22,130. These studies were the first to report the association 
between SNPs near CHRNA5/B4/A3 and CHRNA6/B3 with nicotine dependence 36. Like 
the state of nicotine dependence research prior to this work, alcohol and cocaine 
dependence research had identified only a small number of genes and variants that were 
consistently associated with either alcohol or cocaine dependence. Among these are 
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several weakly associated variants in a number of gamma-amino butyric acid receptors 
(GABRA), alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), the mu 
opioid receptor (OPRM1) and bitter taste receptors (TAS) genes (see 63 for review). The 
first genome-wide significant association for alcohol dependence was with a missense 
variant (rs1229984; R48H) in the ADH1B gene 153. Our group recently demonstrated the 
only other genome-wide significant association with alcohol dependence, a bin of 
common SNPs tagged by rs12912251 near C15orf53 64. The studies of alcohol 
dependence were not as well powered as the studies of cigarette consumption. At most, 
these alcohol dependence studies were performed with a few thousand individuals while 
the meta-analyses of cigarette consumption were performed with 40-70,000 individuals. 
No variant has ever been shown to be genome-wide significantly associated with cocaine 
dependence, however. Of course, few studies have been sufficiently powered to detect 
effects of the size expected (odds-ratios of 1.1-1.5) and no genome-wide association 
studies of cocaine dependence have been performed.  Additionally, no sequencing studies 
had been done prior to this work for either alcohol or cocaine dependence.  
Much work had been done prior to the commencement of this work on 
functionally characterizing the nicotinic acetylcholine receptor genes. For instance, mice 
lacking various nicotinic receptor genes have been shown to have altered behavioral 
response to nicotine 77,90,154. Little work had been done, however, describing the effects of 
variants segregating within human populations within these nicotinic acetylcholine 
receptor genes. Two such studies characterized a handful of variants in CHRNA3, 
CHRNA4 and CHRNB4, but did so in xenopus oocytes and studies of CHRNB4 variants 
were done in combination with CHRNA4 rather than CHRNA3 155,156. Work from our 
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group has shown striking behavioral effects of knocking in the D398N allele into the 
mouse, but this work is yet unpublished. Additionally, no studies have been done wherein 
functional information about rare variants has been integrated into association analyses. 
Some studies have subset, as we have, on variants with higher prior probability of being 
functional (i.e. missense, nonsense, splice-site), but none to our knowledge have 
weighted genotypes based on the results from a functional assay.  
 
Dissertation specific aims 
As very little of the variance in nicotine dependence risk, and the variance in 
nearly all complex traits, can be explained by common SNPs, we began investigating the 
potential role of rare genetic variants in risk for this trait. We undertook pooled 
sequencing of the coding regions and flanking sequence of the CHRNA5, CHRNA3, 
CHRNB4, CHRNA6 and CHRNB3 genes in 710 African Americans (461 nicotine 
dependent (ND) cases and 249 smokers with no symptoms of dependence (controls)) and 
2055 European Americans (1062 ND cases and 993 controls) from the Collaborative 
Study of the Genetics of Nicotine Dependence (COGEND). We then asked whether the 
proportion of individuals harboring at least one rare non-synonymous variant at the 
subset of amino-acid positions conserved across vertebrate species was different in 
nicotine dependent smokers compared to non-nicotine dependent smokers. We 
demonstrated a reduced risk for nicotine dependence among carriers of missense variants 
at conserved residues in CHRNB4 in African Americans and European Americans. 
We then aimed to determine whether rare genetic variation in these genes 
influence risk for developing alcohol or cocaine dependence, two conditions highly 
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comorbid with nicotine dependence. We again undertook pooled sequencing of the 
coding regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 
and CHRNB3 genes in 287 African Americans (147 DSM-IV alcohol dependent cases 
and 140 controls) and 1028 European Americans (480 DSM-IV alcohol dependent cases 
and 548 controls) individuals from the Collaborative Study of the Genetics of Alcoholism 
(COGA). Of these individuals, there were 98 (66%) African American DSM-IV alcohol 
dependent cases who were also DSM-IV cocaine dependent and 184 (38%) European 
American DSM-IV alcohol dependent cases who were also DSM-IV cocaine dependent. 
We then performed follow-up genotyping of all identified non-synonymous variants in all 
available members of the families from which the sequenced individuals came, totaling 
2504 African Americans and 7318 European Americans. For European Americans, we 
found increased DSM-IV cocaine dependence symptoms and increased DSM-IV alcohol 
dependence symptoms among carriers of missense variants in CHRNB3. For African 
Americans, we find decreased cocaine dependence symptoms among carriers of missense 
variants in CHRNA3. These two genes had not previously been implicated in alcohol or 
cocaine dependence specifically. The gene cluster containing the CHRNA5, CHRNB4 and 
CHRNA3 genes was found to be associated with alcohol dependence and cocaine 
dependence, but the linkage disequilibrium bins associated with these phenotypes contain 
SNPs that alter CHRNA5 brain mRNA expression (bin tagged by rs588765) and alter 
protein function (rs16969968, CHRNA5 D398N), neither implicating CHRNA3 or 
CHRNB4 directly.  
Finally, we sought to determine the functional impact of rare variants in CHRNB4 
harbored by individuals in these two cohorts. All variants observed in at least one 
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individual in the COGEND cohort in CHRNB4 (14 variants) were investigated. One 
variant in CHRNA3 (R37H) was also functionally tested as it is in high linkage 
disequilibrium with another rare missense variant (T91I) in CHRNB4. We found several 
variants that alter cellular response either to nicotine or acetylcholine as well as many 
variants that alter cell-surface protein expression as measured by cell-surface ELISA 
without altering either CHRNB4 mRNA or total β4 protein as measured by western blot. 
Further, when we integrate these in vitro findings into a model of association with 
nicotine dependence related traits, we were able to substantially improve the association 
in both African Americans and European Americans. This work strongly suggesting that 
the success of future association analyses in these and potentially many other genes 
across the genome, may depend greatly on functional assessment of observed genetic 
variation. To my knowledge, no other group has attempted to integrate the results from 
function assays directly into association analyses. Many groups, ourselves included, have 
performed tests using only variants fitting some number of criteria, for instance variants 
that occur in functional domains, that perform above a certain threshold on a functional 
assay or occur at evolutionarily conserved sites within the genome, but no group has 
integrated quantitative data regarding the functional effect of variants composing the 
collapsed genotypes using in their analyses.  
These findings support the assertion that variants in or near these nicotinic 
receptor genes are capable of pleiotropic effects. Previous work from our group has 
shown that the common missense variant in CHRNA5 (D398N, rs16969968) affects both 
nicotine and cocaine dependence and that a group of SNPs affecting CHRNA5 mRNA 
expression in the human frontal cortex contribute to alcohol dependence risk and nicotine 
	   164	  
dependence risk 45,139. In both the case of CHRNA5 and CHRNA6-CHRNB3, the allele 
that increases risk for nicotine dependence lowers risk for cocaine dependence or alcohol 
dependence, a fact that makes comorbidity an unlikely cause of the pleiotropy observed. 
The results from this dissertation suggest that rare variants in nicotinic receptors can 
contribute to multiple substance dependence phenotypes. We do not, however, observe a 
rare variant association at any gene and more than one phenotype independently of the 
other phenotypes. We observe that rare variants in CHRNB4 affect nicotine dependence 
and only nicotine dependence and that rare variants in CHRNB3 affect alcohol and 
cocaine dependence. It is possible that these findings are the result of having only 
minimal power to detect such rare variant associations, even given the relatively large 
numbers of individuals sequenced as part of this thesis.  
Overall, this dissertation has identified one novel gene for nicotine dependence 
and two novel genes for cocaine/alcohol dependence, that the variants underlying the 
association of CHRNB4 with nicotine dependence have a significant effect on receptor 
function in vitro and that the magnitude and direction of the functional effect of CHRNB4 
variants on acetylcholine EC50 can be used to improve the observed association with 
nicotine dependence. These are some of the first results implicating rare variants in the 
etiology of human behaviors (nicotine, alcohol and cocaine dependence) and some of the 
first results to identify rare variants in genes that do not cause a more severe, Mendelian 
form of the complex trait under investigation. For instance, PCSK9, one of the first 
examples of a gene containing rare variants contributing to a complex trait, encodes a 
protease that reduces low-density lipoprotein (LDL) receptor levels. Mutations in PCSK9 
had been previously show to cause dominant forms of hypercholesterolemia, so in many 
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ways the association of rare variants in this gene with cholesterol levels was unsurprising. 
Our results suggest that the identification of associations with either common or rare 
variants with truly complex traits require exceedingly large numbers of individuals (we 
sequenced hundreds to thousands of individuals and performed genotyping of observed 
variants in thousands of individuals), will require that those individuals be well 
characterized phenotypically and will likely also require functional characterization of 
observed variants to filter association signal from background noise, i.e. the plethora of 
neutral alleles extant in human populations.  
 
Future directions  
 While one novel gene was found to be associated with nicotine dependence and two 
genes were identified that contribute to risk for alcohol and/or cocaine dependence as the 
result of this work, additional effort will be needed to further validate these findings and 
better understand the contribution of these genes to the phenotypes they affect. This will 
likely be done by sequencing of larger numbers of individuals to look for associations at 
these loci with substance dependence phenotypes and to functionally characterize 
identified associated variants. Further work is necessary to find as of yet undiscovered 
genes and variants that contribute to substance dependence risk. Additionally, this work 
strongly suggests that some variants that contribute to risk of one substance dependence 
may contribute to multiple substance dependences and that further investigation into the 
effect of genetic variants on comorbid phenotypes is warranted. The fact that multiple 
variants in CHRNB3 contribute to both alcohol and cocaine dependence and the fact that 
these variants occur in a gene that harbors common genetic variants associated with both 
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nicotine dependence and cigarette consumption, strongly implicates these nicotinic 
receptor genes specifically in determining one’s risk of becoming dependent on multiple 
substances. In the future, designing a study such that the effects of variants on specific 
drugs independently of one another would be ideal. For instance, having an entire sample 
composed of individuals with no history of drug use or exposure to any drug other than 
the drug under study would ensure that any association observed is due to that specific 
drug. Then if you saw the same variant associated with another drug in a cohort designed 
similarly, i.e. dependent individuals are dependent only on the drug under investigation, 
then one could more conclusively say that the variant has pleiotropic effects on various 
substance dependence phenotypes.  A design in which cases are only dependent on one 
drug, especially if that drug is illegal, may be impossible, however. Currently, studies 
have been designed to maximize power to detect associations between genetic variants 
and a specific drug but have not excluded individuals dependent on other drugs. This 
design has made it difficult to determine the dependence the variant is truly affecting. At 
the very least, improved statistical models are required to de-convolute the complex 
interactions between these drugs, environmental factors and genetic contributors.  
 An expanded effort to identify variants in the genes studied here and to identify 
variants and associations in an unbiased manner, via whole-exome or whole-genome 
sequencing of affected and unaffected individuals, will be necessary to improve our 
understanding of how genetic factors contribute to substance dependence risk. Our group 
has begun sequencing the genomic regions containing the nicotinic receptor genes, 
CYP2A6 and a number of other nicotine metabolizing enzymes in a large number of 
individuals from COGEND. We have obtained African American samples in a similar 
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ascertainment scheme to that used for COGEND as part of the African American Study 
of Nicotine Dependence (AAND) and have begun sequencing this cohort as well. This 
effort will comprehensively evaluate the contribution of both common and rare variants 
in these regions with respect to their contribution to nicotine dependence risk. While most 
of these individuals were sequenced as part of this dissertation, several hundred were 
merely genotyped for variants observed in sequenced individuals. It is possible, then, that 
the added variants discovered in these newly sequenced individuals will give the rare 
variant associations the power needed to observe significant associations between some 
of these genes and nicotine dependence.  Of course, the next important step in 
determining the genetic underpinnings of nicotine dependence is to perform either exome 
or whole-genome sequencing in this cohort, or ideally an expanded cohort, to test for 
associations between rare variants in each gene across the genome and risk for nicotine 
dependence. When sequencing becomes sufficiently inexpensive, this study is an 
inevitability. Given the expensive nature of whole-genome sequencing and even exome 
sequencing at this point in time, paired with the fact that very large numbers of 
individuals are necessary to obtain sufficient power to observe significant genetic 
associations either with common variants, collapsed rare variants or rare variants using 
statistical methods like SKAT or the c-alpha test, it is likely most efficient to perform 
targeted sequencing of a large number of individuals. If one has sufficient funds, however, 
performing exome-sequencing in the entire sample of individuals is preferable as it 
allows for an unbiased determination of the contribution of rare variants to disease risk.    
 Despite the extensive in vitro work done as a part of this dissertation, further work 
can be done to characterize these variants in vitro. Additionally, it has yet to be 
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determined if the variants contributing to the observed associations have an effect on 
function and behavior in vivo.  In order to further test the functional effect of the 
observed variants in CHRNB4, or other genes, in a more suitable context, it is now 
possible to derive induced pluripotent stem cells (IPSCs) from fibroblasts obtained from a 
skin biopsy. These IPSCs can then be differentiated into neurons by incubating the IPSCs 
with specific neuronal differentiation factors. These differentiated cells are capable of 
producing action potentials and express markers of various neuronal populations. IPSCs 
can be derived from individuals with and without a given genetic variant and the 
electrophysiological properties of their IPSC derived neurons can be determined. Further, 
current technology including zinc-finger nucleases, TALEN effectors and CRISPR-Cas9, 
can be used to alter a specific nucleotide base and compare the properties of cells with or 
without a mutation while retaining identical genetic background. This would likely 
reduce the signal to noise ratio as variance induced by comparing individuals with 
differing genetic backgrounds would no longer be an issue. In order to investigate the 
effects of observed variants in vivo, a reasonable experiment would be to construct either 
lentivirus or adenovirus constructs that are able to infect live cells and express wild-type 
or variant forms of nicotinic receptor subunits as well as GFP as a marker of infection. 
Upon infecting interesting brain regions, for instance the medial-habenula or 
interpeduncular nucleus, slices could be made and electrophysiological measurements 
taken to determine the effect of variants on receptor function in vivo. Additionally, living 
mice infected with these constructs can be subjected to nicotine conditioned place 
preference testing to determine if expression of variant receptors lead to altered nicotine 
preference or aversion. Knockout mice for the receptor subunit under investigation, in 
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this case CHRNB4, would be preferable to wild-type mice as all observed CHRNB4 
would necessarily be introduced via viral infection. A far more expensive alternative to 
this lentiviral/adenoviral approach would be to create knock-in mice with only a single 
amino acid changed and then perform the above-mentioned experiments on the resultant 
mice. This can now be more readily done with the newly described TALEN or CRISPR-
Cas9 systems of genome editing, but remains far more expensive than the 
lentiviral/adenoviral approach. This approach would be preferred generally over 
expression of variant forms of CHRNB4 in specific brain regions as it does not suppose a 
priori which brain regions are responsible for potential behavioral effects. Additionally, 
resultant mice can be propagated without the need to grow viruses or perform stereotaxic 
injections. One further disadvantage to this technique is that it is not as easy to investigate 
a large number of variants in a short amount of time, a possibility when using the viral 
expression technique.  
 There is much work to be done in the identification of new variants and genes 
underlying risk for nicotine, alcohol and cocaine dependence and the characterization of 
associated variants and genes in cellular and animal models. Both of these avenues of 
investigation undertaken as part of this dissertation remain to be fully explored. It is my 
hope that others in our laboratory and other groups will replicate the findings presented 
here, expand upon them and utilize the insights drawn regarding the integration of 
functional information into association analyses to identify other novel genes involved in 
complex diseases.  
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